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N-methyl-D-aspartate (NMDA) receptors are members of the ionotropic glutamate 
receptor family that have critical functions in neural plasticity as well as a number of nervous 
system pathologies.  NMDA receptors have a great deal of diversity in the subtypes expressed in 
different regions of the nervous system throughout the course of development. A greater 
understanding of NMDA receptor functioning in the nervous system is therefore highly desirable 
to researchers and clinicians, but this understanding is limited by the current set of selective 
pharmacological tools.  The goal of the work in this dissertation is to gain a greater understanding 
of how highly selective NMDA receptor antagonists can be developed from a distinct group of 
peptides derived from the venom of marine cone snails known as the Conantokins, natural 
products that block NMDA receptors in a subtype-selective manner.  The work in this dissertation 
aims to further this objective through three separate approaches.  In Chapter 2, a novel 
conantokin, Conantokin-Br, is functionally characterized, and structure-activity relationship 
studies are performed to identify sequence determinants of subtype selectivity.  In Chapter 3, 
NMDA receptor NR2 subunit chimeras are generated and used to identify determinants of 
selectivity towards Conantokin-R and ConantokinRl-B on the glutamate binding subdomains of 
the NR2 subunits.  In Chapter 4 the selective conantokin ConantokinRl-B is used to identify 
NR2B-containing NMDA receptor subtypes present in dissociated Ventral Respiratory Column 
cells.  In Chapter 5, these results are summarized, and the overall significance of the work is 
described.  It is hoped that the experiments performed in this work will one day lead to highly 
selective compounds that will further the frontiers of investigating the underlying functions and 
therapeutic potential of targeting NMDA receptors.
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NMDA Receptors: physiological roles, expression patterns, and pharmacology 
N-Methyl-D-Aspartate (NMDA) receptors are members of the ionotropic glutamate 
receptor superfamily of ion channels.  Similar to other members of the glutamate receptor 
superfamily, including α-­‐Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors and kainate receptors, NMDA receptors bind the excitatory amino acid glutamate to 
mediate cation flow across a membrane voltage potential in neurons.  A number of functional 
features distinguish NMDA receptors from other types of ionotropic glutamate receptors, 
including: 1) the requirement of the co-agonists glycine or D-serine for activation, 2) calcium-
permeability through the ion channel pore, and 3) the presence of a voltage-dependent Mg2= 
blockade of ion flow in the channel.  Among these unique functional distinctions, the presence of 
a voltage-dependent Mg2+ blockade of ion flow appears to be important for the process of 
coincidence detection, a fundamental mechanism thought to underlie the processes of synaptic 
plasticity and learning and memory in the nervous system (Seeburg et al., 1995).  In support of 
this hypothesis, pharmacological blockade of NMDA receptors has been shown to impede 
learning and memory of many functional tasks in rodents (Morris, 2013; Davis et al., 1992). 
 In addition to being implicated in the fundamental processes of learning and memory, the 
dysfunction of NMDA receptors also plays a role in a number of pathological processes that 
affect the nervous system.  In the spinal cord, NMDA receptors are thought to be involved in the 
development of chronic neuropathic pain (Zhou et al., 2011).  In the brain, NMDA receptors are 
thought to play a role in epilepsy, Parkinson’s disease, Alzheimer’s disease, depression, and 
psychosis (Ghasemi et al., 2011; Xu et al., 2012; Calabresi et al., 2013; Zarate et al., 2013; 
Pochwat et al., 2013; Cioffi, 2013).  Thus, there has been a tremendous amount of interest in 
developing therapeutics targeted to NMDA receptors.   While early studies utilizing nonselective 
NMDA receptor antagonists demonstrated that they were generally effective at ameliorating 
many of these conditions, many human trials were not continued due to a number of side effects, 
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thought to be due to a lack of specificity towards the particular NMDA receptors implicated in 
these disorders. 
 Among the obstacles in developing highly specific therapeutics is the tremendous 
diversity among the NMDA receptor class of glutamate receptors.  NMDA receptors comprise at 
least three different gene families, including the NR1 (which bind glycine), NR2 (which bind 
glutamate), and NR3 subunit genes (which also bind glycine) (Cull-Candy et al., 2001).  To add 
to this complexity, there are eight different splice variants for the NR1 subunit, for separate NR2 
subunit genes (NR2A-NR2D), and two NR3 genes (NR3A and NR3B) (Cull-Candy et al., 2001).  
Functional NMDA receptors are heterotetramers, consisting of at least two NR1 subunits, and a 
potential combination of any NR2 or NR3 subunits (Ulbrich and Isacoff, 2008; Schuler et al., 
2008).   
The precise subunit combinations expressed in the mammalian nervous system are not 
known; however immunohistochemistry and RNA expression studies have revealed that NMDA 
receptor subunit genes are distributed in the nervous system in a region-specific and 
developmentally-regulated manner (Rigby et al, 1996; Riva et al., 1994; Laurie et al., 1997).  In 
general, the obligatory NR1 subunit (and its many splice variants) is ubiquitously-expressed in 
the nervous system (Pujic et al., 1993; Laurie and Seeburg, 1994).  Among the NR2 subunits, the 
NR2A subunit is expressed in a majority of regions in the central nervous system, the NR2B 
subunit is expressed predominantly in the forebrain and hippocampal regions, the NR2C subunit 
is expressed at highest concentrations in the cerebellum, and the NR2D subunit is largely 
expressed in the midbrain and brainstem regions (Laurie et al., 1997).   During development, 
changes in NMDA receptor subunit expression occur in early postnatal mammals, with the NR2B 
and NR2D subunits generally declining in expression, and the NR2A and NR2C subunits 
increasing in abundance (Laurie et al., 1994).   
Pharmacological agents targeting specific subtypes have been developed; however, 
antagonists targeting particular NMDA receptor subtypes are relatively few in comparison to the 
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number of potential NMDA receptor subtypes.  Among the selective antagonists, the majority are 
targeted towards particular NR2 subunits, which bind the excitatory amino acid glutamate.  Small 
molecules, including ifenprodil and derivatives, are highly specific to NMDA receptor subtypes 
containing NR2B subunits (Fischer et al., 1997; Gill et al., 2002).  In addition, novel classes of 
small molecules have been developed that target the NR2C and NR2D subunits with some 
preference over NR2A and NR2B subtypes (Mosley et al., 2010). Notably, many of these 
molecules have been reported to have off-target (non-NMDA receptor) activities that should be 
considered when assessing the effects of these compounds (see Supplementary Information, 
Gowd et al., 2012).  Thus, additional selective antagonists, with minimal activity on non-NMDA 
receptor targets, would be highly desirable for research and therapeutics. 
 
Conantokins: subtype selective conopeptide NMDA receptor antagonists 
Conantokins are peptide antagonists of NMDA receptors derived from the venom of 
marine cone snails of the genus Conus.  Conantokins are distinct among the conopeptides in that 
they generally lack disulfide bonds are enriched in the posttranslationally-modified amino acid 
gamma carboxyglutamate (gla).  The presence of gla residues contribute to the helical structure of 
conantokins in solution upon binding of divalent cations (Chen et al., 1998; Rigby et al., 1997; 
Warder et al., 1998).  Thus far, 15 different conantokins from 8 different species have been 
functionally characterized in the literature (Gowd et al., 2008; Gowd et al., 2010; Gowd et al., 
2012; Haack et al., 1990; Jiminez et al., 2002; Mena et al., 1990; Platt et al., submitted; Teichert 
et al., 2007; Twede et al., 2009a; White et al., 2000).   
 Conantokins are thought to competitively inhibit ion flow through NMDA receptors by 
acting at the glutamate binding site on the NR2 subunits (Donevan and McCabe, 2000).  In 
accordance with this hypothesis, conantokins generally selectively block NMDA receptor 
subtypes depending on which NR2 subunits are expressed in the complex (see Twede et al., 
2009b).  The majority of conantokins preferentially target NMDA receptors containing the NR2B 
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subunit, and have varying degrees of inhibition on NMDA receptor subtypes containing other 
NR2 subunits (Reviewed in Twede et al., 2009b).  Recently, however, conantokins were 
identified that show some preference for NR2D-containing NMDA receptor subtypes (Platt et al., 
submitted).    
 Along with other conantokins, ConantokinG (ConG) from Conus geographus, has 
demonstrated therapeutic potential in preclinical trials for the treatment of epilepsy, 
neuroprotection from focal ischemia, and neuropathic pain (Bialer et al., 2002; Malmberg et al., 
2003; Reviewed in Twede et al., 2009b; Williams et al., 2000;).  ConG has additionally reached 
Phase I clinical trials for the treatment of epilepsy in humans (Bialer et al., 2002).  Unlike many 
other NMDA receptor antagonists, conantokins have shown relatively low toxicity and few side 
effects in animal models (Malmberg et al., 2003).  This relatively low toxicity has been attributed 
to specificity towards the particular NMDA receptor subtypes affected in these nervous system 
disorders, in addition to a lack of off-target activity (Malmberg et al., 2003; see Gowd et al., 
2012).  Recently, the discovery of ConantokinRl-B (ConRl-B), a conantokin with anticonvulsant 
activity and unprecedented selectivity among the conantokin family (greater than ~100-fold 
against all other subtypes) for the NR2B subunit (Gowd et al, 2012) has demonstrated further 
potential for the development of highly selective antagonists targeted towards each NMDA 
receptor subtype.   
 To develop and discover additional highly selective conantokin peptides and analogues 
more effectively, two problems must first be addressed.  First, a greater understanding is needed 
of how and to what extent the primary amino acid sequences (and subsequent structures) of 
conantokin peptides can be used to predict (and design) conantokin sequences that are capable of 
targeting each particular NMDA receptor subtype with a high degree of selectivity.  Structure-
activity relationship studies have demonstrated, for instance, that certain amino acid positions 
within these peptides are critical for governing both rudimentary activity and, to some extent, 
subunit selectivity (Klein et al., 2001; Sheng et al., 2007; Sheng et al., 2010).  Second, a greater 
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understanding is needed of how conantokins interact with the binding site(s) on the each of the 
NR2 subunits to determine selectivity towards each NMDA receptor subtype.  While some work 
has been performed to address both of these questions, these studies were largely performed, by 
examining differences between selectivity towards two of the NMDA receptor subtypes (those 
containing either the NR2A or NR2B subunits) (Klein et al., 2001; Sheng et al., 2007; Sheng et 
al., 2009; Sheng et al., 2010).  Thus, the question of how each conantokin interacts with each of 
the four NR2 subunits to result in subtype selectivity is an area of potential research interest.  In 
addition, the question of how subtype-selective conantokins can be used to dissect the expression 
patterns of particular NMDA receptor subtypes in the nervous system is an area of research 
interest. 
 
Work described in this dissertation 
The work described in this dissertation aims to further the efforts of developing and 
characterizing highly selective NMDA receptor antagonists derived from the Conantokin family 
of peptides.  In Chapter 2, a novel conantokin from Conus brettinghami, Conantokin-Br, is 
functionally characterized; high potency on NR2D-containing NMDA receptors allowed for a 
structure-activity relationship study to be performed, resulting in the identification of the amino 
acid at position 5 in the peptide as a determinant of NR2D selectivity.  In Chapter 3, structure 
function studies are used to elucidate the regions of interaction between two conantokins, 
Conantokin-R and ConantokinRl-B and the two NR2 subunits, NR2B and NR2D; results indicate 
that the two conantokins interact with similar regions (yet different amino acids) in the glutamate 
binding domains to determine the subunit selectivities of the peptides.  In Chapter 3, the NR2B 
subtype-selective conantokin ConRl-B is used in a calcium-imaging assay of dissociated ventral 
respiratory column cells to identify NMDA receptor subtypes expressed in this region; results 
indicate a distinction between NR2B-containing and other NMDA receptor subtypes among two 
major cell classes with in this region of the brain.  Lastly, in Chapter 5, future directions of 
	   7	  
research are discussed in the context of the results described in the experiments herein.  It is 
hoped that this work can be used to ultimately gain an understanding of the individual functional 
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ABSTRACT: Conantokins are venom peptides from marine cone snails that are NMDA receptor
antagonists. Here, we report the characterization of a 24 AA conantokin from Conus brettinghami
Coomans, H. E., Moolenbeek, R. G., and Wils, E. (1982) Basteria 46 (1/4), 3-67, conantokin-Br
(con-Br), the first conantokin that does not have the conserved glutamate residue at position 2.
Molecular modeling studies suggest that con-Br has a helical structure between residues 2-13.
In contrast to other characterized conantokins, con-Br has a high potency for NMDA receptors with
NR2D subunits. To identify determinants for NR2D potency, we synthesized chimeras of con-Br and
conantokin-R (con-R); the latter has a ∼30-fold lower potency for the NR2D subtype. The
characterization of two reciprocal chimeras (con-Br/R and con-R/Br), comprising the first 9-10
N-terminal AAs of each conantokin followed by the corresponding C-terminal AAs of the other
conantokin demonstrates that determinants for NR2D selectivity are at the N-terminal region.
Additional analogues comprising 1-3 amino acid substitutions from each peptide into the
homologous region of the other led to the identification of a key determinant; a Tyr residue in
position 5 increases potency for NR2D, while Val at this locus causes a decrease. The systematic
definition of key determinants in the conantokin peptides forNMDAreceptor subtype selectivity is an
essential component in the development of conantokin peptides that are highly selective for each
specific NMDA receptor subtype.
The glutamate receptor superfamily comprises a large
number of different genes, each encoding a subunit that
assembles to form the functional receptor complex, be-
lieved to be composed of four primary subunits (2).
Glutamate receptors are traditionally divided into three
classes, R-amino-3-hydroxy-5-methyl-4-isoxazole propio-
nic acid (AMPA1) receptors, NMDA receptors, and kai-
nate receptors, on the basis initially of pharmacological
criteria (3-5). Each class has separate, but overlapping
physiological roles and corresponding links to various
pathologies in the nervous system. Dysfunction among
all three classes has been implicated in epilepsy (6),
Parkinson’s disease and Alzheimer’s disease (7) as well as
excitotoxic neuronal death (8). Additionally, NMDA
receptors are thought to be involved in chronic pain (9)
and mechanisms of drug and alcohol addiction (10, 11).
NMDAreceptors havemany properties that distinguish
them fromothermembers of the glutamate receptor super-
family (i.e., voltage-dependent Mg2+ inhibition, perme-
ability to Ca2+, and the requirement of the coagonists
glycine or D-serine), andmultipleNMDAreceptor subunit
genes contribute to their functional diversity (12). The
NR1 subunit, which binds glycine, has eight splice var-
iants, and is ubiquitously expressed in the central nervous
system (5). Four separate genes (NR2A-NR2D) encode
different isoforms of the NR2 subunit, which binds gluta-
mate; expression of different NR2 genes varies according
to both regional and temporal expression patterns in the
brain (12). In addition, twoNR3genes havebeen identified
(NR3A-NR3B), which also vary in their regional and
temporal expression patterns (13). The assembly of a
functional tetrameric complex is thought to require the
presence of two obligatory NR1 subunits and a combina-
tion of modulatory NR2 or NR3 subunits; studies exam-
ining receptor subunit assembly indicate that NR1
subunits form heterodimers with NR2 or NR3 subunits
at the initial stage in assembly (14).
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Although much remains to be elucidated, pharmacolo-
gical evidence suggests that different NMDA receptor
subunit combinations may play different roles in the
physiology and corresponding pathology of the central
nervous system. For instance, NMDA receptor antago-
nists that selectively inhibit receptors containing theNR2B
subunit have been implicated in the treatment of epilepsy
and chronic pain, whereas more broadly selective NMDA
receptor antagonists generally result in toxicity or intoler-
able side effects in the same assays (15). Conversely,
more broadly targeted NMDA receptor antagonists were
effective at preventing axonal demyelination in models of
ischemia,whereasNR2B-specific antagonists hadno effect
on myelin degradation, suggesting that the antagonism of
non-NR2B subtypes mediates this protective effect (16).
Interestingly, evidence suggests the effects of NR2B-
selective antagonists show correspondence to temporal
and regional expression patterns in the brain. For instance,
NR2B expression is enriched in hippocampal and tempor-
al regions in adult rats (17), corresponding to areas of the
brain affected in many types of epilepsy, and suggesting
a possible mechanism of action. It remains to be
determined whether antagonists targeted to other NR2
subunits, such as NR2D, which is enriched in midbrain
regions (12), affect the physiology and pathophysiology
associated with these brain regions.
In order to understand the function of each individual
receptor subtype in the intact nervous system, the standard
approach that has been employed is gene knockout tech-
nology. As is the case for all ion channel complexes with
multiple subunits, glutamate receptor gene knockouts
need to be complemented with pharmacological agents
that are as highly subtype selective as possible. It is
particularly desirable to find ligands that bind at subunit
interface sites that permit the ligand to interact with
determinants on two different subunits. There is a funda-
mental difficulty with using knockout technology exclu-
sively to assess ion channel function for those families in
which a wide variety of different receptor subunits can be
assembled as heteromeric complexes in vivo. Ablating the
function of a gene that encodes a single type of subunit can
result in a very complex phenotype, in which multiple
functional complexes with different subunit compositions
and physiological roles are affected. The phenotype of
NMDA receptor NR1 subunit gene knockout mice, for
instance, is not straightforward: concomitant expressionof
the NR2B subunit is markedly reduced, and neonates do
not survive long after birth (18).
One often-effective approach to obtaining subtype se-
lective pharmacological agents to complement gene
knockout technology is to startwith the pharmacologically
active components of animal venoms. Unfortunately,
there have not been a large number of venom components
characterized to date that target glutamate receptors. The
polyamine toxins found in spider venoms are one such
class (19). A promising general source that needs to be
explored further are the venoms of cone snails; these have
proven tobe very rich in families of peptides targeted to ion
channels. There are two Conus peptide families that target
glutamate receptors identified so far, the conantokins, that
act as NMDA receptor antagonists (15, 20-22), and the
recently identified con-ikot-ikots, which are targeted to
AMPA receptors (Walker, C. et al., submitted for publica-
tion).Allmembers of the conantokin family targetNMDA
receptors but with differing subtype selectivity; conversely,
the con-ikot-ikots appear to exclusively target AMPA
receptors, although many properties of this peptide family
remain to be investigated (23-25).
For both of these families, the number of Conus species
that have been identified with venom components targeted
to glutamate receptors has been surprisingly small. Among
the conantokins, peptides from only six species have been
characterized (20, 24-28), and within the con-ikot-ikot
family, a peptide from a single Conus species has been
characterized.
We recently initiated an expanded effort to systemati-
cally examine new Conus species (29) for venom compo-
nents that selectively target glutamate receptor subtypes.
Previous work has used synthetic peptide analogues to
identify some of the determinants of NR2A and NR2B
subunit selectivity in conantokins (30) (reviewed in ref 31).
To expand upon this approach, we have begun to search
for sequence variations among native conantokins that
govern target specificity.
In this article,wedescribe a newpeptide, conantokin-Br,
from Conus brettinghami (1) that has a number of proper-
ties that are novel, including higher relative potency for the
NR2D subunit than has been previously reported for
conantokin peptides. We also characterized chimeras
between conantokin-Br and a conantokin with different
subunit selectivity, conantokin-R. This provided an
opportunity to assess the relative importance of primary
sequence variations with respect to activity on different
NMDA receptor subtypes. This study has led to a number
of structure/function insights for developing ligands
with divergent selectivity for different NMDA receptor
subtypes based on the conantokin family of conopeptides.
MATERIALS AND METHODS
Isolation of the Conantokin-Br Clone.An oligo (DHOG
450 50-GCCCGTGCCTAGGATTA-30) was designed to
the signal sequence of known conantokins, conantokin-R
and conantokin-G. This oligo was used to probe a cDNA
library constructed from the venom duct of C. brettin-
ghami using Southern hybridization as previously de-
scribed (32). The identified clone was sequenced using
Sequenase version 2.0.
Peptide Synthesis and Cleavage. Native peptides and
analogues were synthesized using Fmoc-protected amino
acids in an ABI model 430A automated peptide synthe-
sizer, courtesy of Dr. Bob Schackmann and Scott
Endicott of the Peptide/DNA Core Facility at the Uni-
versity of Utah. Each peptide was cleaved from 25 to
50mg resin using 1mLofReagentK (trifluoroacetic acid/
H2O/1,2-ethanedithiol/phenol/thioanisole, 82.5:5:2.5:5:5
by volume). Each peptide was agitated for a minimum of
1.5 h at room temperature, with an additional 0.5 h for
each arginine residue in the individual amino acid se-
quence. The cleavagemixture was filtered and precipitated
with cold methyl-tert-butyl ether (MTBE). The crude
peptides were then collected by centrifugation at 5000g
for 8 min and washed two times with cold MTBE. The
washed peptide pellet was dissolved in 60% acetonitrile in
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0.1% trifluoroacetic acid and purified using a Vydac C18
semipreparative HPLC column (10 ! 250 mm, 5 μm
particle size). Each peptide was eluted from the column
using a linear gradient of 10% buffer B (90%ACN, 0.1%
TFA) to 50% buffer B in 40 min, at 4 mL/min.
Oxidative Peptide Folding. Conantokins containing
two C-terminal cysteines (con-R and con-R variants)
were oxidized using either Clear-Ox resin (Peptides Inter-
national, Inc.), as described previously (33), or 1:1 oxi-
dized/reduced glutathione. To prepare Clear-Ox resin for
the oxidation reaction, 20 mg of the resin was activated in
dichloromethane for 30 min and washed two times each
with 1mLof dimethyl formamide, 1mLofmethanol, and
1 mL of acetonitrile H2O (1:1) solution. For the Clear-Ox
reaction, 200 nmol of peptide per reaction was oxidized
for 2 h in a solution containing 20 mg of the activated
resin and 100 mM Tris HCl. The reaction was then
quenched by adding formic acid (8% final concentra-
tion), filtered under vacuum, and washed with 0.01%
TFA inH2O to remove the peptide from the resin. For the
glutathione reaction, 200 nmol of peptide per reaction
was oxidized using a mixture of the following reagents:
0.01% TFA in H2O, 1 M tris HCl/100 mM EDTA,
10 mM oxidized/10 mM reduced glutathione, and nano-
pure H2O (1:1:1:7; final peptide concentration: 20 μM).
Glutathione reactions were carried out for 45-60 min
and quenched with 8% formic acid. Folded peptides were
purified on a Vydac C18 semipreparative HPLC column
(10 ! 250 mm, 5um particle size) and eluted using a
gradient of 10% buffer B to 50% buffer B in 40 min, at
4 mL/min.
Heterologous Expression of NMDA Receptors in Xeno-
pus Oocytes. The rat NMDA receptor clones used were
NR2A, NR2B, NR2C, NR2D, and NR1-3b; GenBank
numbers AF001423, U11419, U08259, U08260, and
U08266, respectively. In vivo, the NR1-3 and NR1-b
splice variants are expressed in the hippocampus and
cerebral cortex of adult rats (34); the NR2 subunits vary
in their regional and developmental expression (see
ref 12). All of the expression clones were driven by a T7
promoter and were used to make capped RNA (cRNA)
for injection into the oocytes of Xenopus laevis frogs.
cRNA was prepared in vitro using Ambion RNA tran-
scription kits (Ambion, Inc.) according to the manufac-
turer’s protocols. To expressNMDAreceptors, 2-5 ng of
cRNA for each subunit was injected per oocyte. Oocytes
were maintained at 18 !C in ND96 solution (96.0 mM
NaCl, 2.0 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and
5 mM HEPES at pH 7.2-7.5) containing antibiotics
(septra, amikacin, and pen/strep). All voltage-clamp
electrophysiology was done using oocytes 1-6 days
postinjection.
Two-Electrode Voltage Clamp Electrophysiology. All
oocytes were voltage clamped at -70mV at room tem-
perature. Oocytes were gravity perfused with Mg2+-free
ND96 buffer (96.0 mM NaCl, 2.0 mM KCl, 1.8 mM
CaCl2, and 5 mMHEPES at pH 7.2-7.5). Mg2+ was not
included in the ND96 buffer because Mg2+ blocks
NMDA receptors at the voltage potential used to clamp
oocytes (-70 mV). To reduce nonspecific absorption of
peptide, bovine serum albumin (BSA) was added to
ND96 buffer at a final concentration of 0.1 mg/mL. To
elicit current from oocytes expressing NMDA receptors,
one-second pulses of gravity-perfused agonist solution
were administered at intervals of 60 s, 90 s, or 120 s,
depending on the rate of receptor recovery from desensi-
tization. Agonist solution comprised glutamate and
coagonist glycine suspended in Mg2+-free ND96 buffer
at final concentrations of 200 μM and 20 μM, respec-
tively. Buffer was perfused continuously over the oocytes
between agonist pulses, except during equilibration per-
iods. During the equilibration period, buffer flow was
halted for either 5 or 10 min to create a static bath for
application of either peptide (suspended in ND96 buffer
at various concentrations) or control solution (ND96
buffer alone). The length of equilibration period for each
peptide was equal to or greater than the time necessary
to achieve maximal current inhibition at a given concen-
tration. The effect of a peptide on NMDA receptor-
mediated current was determined by measuring the
amplitude of the first agonist-elicited current pulse
immediately following the equilibration period as a
percentage of the amplitude of the baseline current
(agonist-elicited current immediately preceding the equi-
libration period). Data acquisition was automated by
a virtual instrument made by Doju Yoshikami of the
University ofUtah. Concentration-response curveswere
generated using Prism software (GraphPad Software,
Inc.), using the following equation, where nH is the
Hill coefficient, and IC50 is the concentration of
peptide causing half-maximal block: % response =
100/{1 + ([peptide]/IC50)
nH}.
MolecularModeling.Conantokin-T (con-T) and con-G
sequences were aligned to con-Br and its chimera con-R/
Br using the CLUSTALW (35) web-based program
(Table S1, Supporting Information). Since the alignments
with con-T had a higher percentage identity score, the
con-T coordinates (PDB code-name: 1ONT) were used
for homology modeling. Modeling of con-R and con-Br/
R chimera was precluded due to a lack of an appropriate
conantokin model containing a disulfide bridge.
γ-Carboxyglutamate residues were replaced with gluta-
mic acid residues using the PyMOL (36) program.
PSIPRED (37), a protein secondary structure prediction
program, was employed to verify the homologymodeling
results. To further expand the structural analysis of the
modeled conantokins, we submitted the resulting coordi-
nates to molecular dynamics (MD) simulation with the
AMBER 8.0 (38) program and ff99SB AMBER force
field. Conantokins were solvated with the explicit water
model TIP3P (39), with the box-size extended approxi-
mately 12 A˚ away from the solute atoms. To neutralize
the charge of the system, a magnesium cation was added
using the LEaP program from the AmberTools package.
To monitor conformational changes for all amino acid
residues, we used the DSSP method (40) from the Ptraj
program. The energy minimization procedure involved
5000 steps of the steepest descent (41) (SD) method and
15000 steps of the conjugate gradient (42) (CG) method.
To heat up the system, a 50 psMD simulation was carried
out. The initial temperature was 100 K, and the final was
298 K. Neither restraints nor constrains were applied
during the heating step. Next, a 1.25 ns MD simulation
with the 2.0 fs time step was performed. The temperature
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was kept at 298 K with Berendsen coupling (43) and 10 A˚
cutoff applied. The SHAKE algorithm (44) was used on
hydrogen atoms with a tolerance of 0.00005 A˚.
RESULTS
Analysis of a Clone Encoding a Conantokin from C.
brettinghami.A specimen ofConus brettinghami collected
by trawlers from around Manila Bay, Philippines was
used to construct a cDNA library. Conus brettinghami is
conventionally regarded as a form or subspecies ofConus
sulcatus: in this view, Conus sulcatus is regarded as a
variable species distributed broadly in the IndoPacific
region from Japan to the Bay of Bengal in South India,
and east to Fiji. Conus sulcatus is a somewhat confusing
taxon. However, the Manila Bay populations are not
typicalConus sulcatus but rather the form known bymost
taxonomists as Conus sulcatus brettinghami, which has a
narrower and smoother shell than the typical form
(see Figure 1). Although the standard treatise on cone
snail taxonomy (45) regards Conus sulcatus brettinghami
as merely a form of Conus sulcatus, more recent
data suggests that it is a different species from typical
Conus sulcatus (Olivera, B., and Bouchet, P., manuscript
in preparation). The conantokin peptide described
below was characterized from a cDNA clone from
C. brettinghami; no independent assessment of cDNAs
from typical Conus sulcatus has been carried out to
date. Although there is no molecular phylogenetic data
on this species complex available at the present time, we
regard C. brettinghami as a distinct species from C.
sulcatus.
A cDNA clone encoding a peptide precursor highly
homologous to previously identified sequences in the
conantokin gene superfamily was identified, as described
under Materials and Methods. The amino acid sequence
predicted from the encoded open reading frame of
the clone (Figure 2) is compared to the sequences of
three previously characterized conantokin precursors.
The high degree of homology is consistent with the gene
belonging to the conantokin superfamily.
As a member of the conantokin superfamily,
most glutamate residues in the mature toxin region
are predicted to be post-translationally modified to
γ-carboxyglutamate. The glutamate residue at position
12, however, was predicted not to be post-translationally
modified based on the pattern of γ-carboxylation of
previously characterized conantokins purified from
venom (i.e., a Gla every 3-4 residues in the N-terminal-
to-middle of the mature peptide). It has been shown for
con-G in NMR studies that this pattern results in the
alignment of Gla residues on one face of the peptide in
a linear fashion to form a calcium binding motif allowing
for stabilization of the R helix conformation (46). Analy-
sis of the conantokin-T sequence purified from venom
suggests that Glu residues in positions that do not adhere
to this pattern are not modified to Gla; for instance, the
FIGURE 2: Con-Br peptide precursor and predictedmature toxin sequences, compared to previously characterized conantokin precursors. In the
mature toxin region, Glu residues either known or predicted to be post-translationally modified to Gla are indicated by γ.
FIGURE 1: Forms ofConus sulcatus andConus brettinghami, the species that produces conantokin-Br. The shells on the extreme left and right are
Conus sulcatus; the twomiddle shells are generally calledConus sulcatus brettinghami; two varieties are shown.As is discussed in the text, we regard
Conus brettinghami as a distinct species, not as a subspecies or form of C. sulcatus. The shell on the extreme left is a variant of the typical form.
Venom ducts of several specimens of Conus sulcatus brettinghami from Manila Bay were pooled; this was the source of the cDNA clone that
yielded the conantokin sequence. The specimens resembled the shell that is second from left.
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Glu at position 16 (1AA from the nearestGla) is not post-
translationally modified in the native sequence (20). The
predicted sequence of con-Br was chemically synthesized
as described under Materials and Methods.
The mature toxin sequences of the venom-purified
conantokins con-G and con-R are shown in Figure 2
andTable 1 for comparison.Unlike any other conantokin
characterized thus far, the sequence of theC. brettinghami
clone predicts an aspartate at sequence position 2 rather
than the canonical (nonpost-translationally modified)
glutamate; the conserved glutamate at this position was
found to be critical for NMDA receptor activity in other
conantokins (47, 48).
Functional Characterization of Conantokin-Br. The
amino acid sequence of con-Br is clearly homologous
with other members of the conantokin family, which are
NMDA receptor antagonists. To assess its effects on
NMDA receptors, we used two-electrode voltage-clamp
electrophysiology to measure current traces from Xeno-
pus oocytes heterologously expressing various combina-
tions of NR1-3b andNR2 subunits. Con-Br was applied
to oocytes and allowed to equilibrate for 10 min. The
effect of the peptide was determined by measuring the
agonist-elicited current in the absence (as a control) and
presence of the peptide.
Con-Br (1 μM) blocked most of the current in the
NR1-3b/NR2B subtype (Figure 3A), confirming its
activity as an NMDA receptor antagonist. Strikingly, a
similar level of current inhibition was observed at the
same concentration for the NR1-3b/NR2D subtype
(Figure 3B), suggesting con-Br is the most potent con-
antokin active onNR2D-containingNMDA receptors of
any characterized thus far.
Concentration-response curves for each of the NR2
subunits (A-D) separately coexpressed with the NR1-
3b subunit were determined (see Table 2 and Figure 4A);
con-Br had the greatest inhibitory effect on the NR2B
subunit, and the order of potency for con-Br was
NR2B > NR2D > NR2A > NR2C.
Localization of Determinants for Subtype Selectivity.
Previous studies have demonstrated that, for NMDA
receptors containing NR2A and NR2B subunits, the
structural determinants of subtype selectivity in conanto-
kin-G and conantokin-T can be localized to discrete
amino acid residues within the peptides (30, 49). To
determine whether the unique subtype selectivity profile
of con-Br can be attributed to key localized amino acid
residues, we synthesized chimeric analogues of con-Br,
which weakly discriminates between NR2B and NR2D,
and conantokin-R (con-R), which discriminates strongly
against NR2D in favor of NR2B (28). Two chimeric
analogues were synthesized with the N-terminal end of
one peptide attached to the C-terminal end of the other
peptide with a crossover point at the third Gla residue
(Gla 10 in con-Br and Gla 11 in con-R). Thus, con-Br/R
had the N-terminal residues of con-Br and the C-terminal
residues of con-R and con-R/Br, the N-terminal amino
acids of con-R, and theC-terminal amino acids of con-Br.
The analogues were tested for subtype selectivity on
NR1-3b/NR2B and NR1-3b/NR2D receptors ex-
pressed inXenopus oocytes (Figure 4 and Table 2). Parent
peptides were used as controls. Because previously pub-
lished results for the con-R activity on NR2D were
obtained using different methods (28), a concentration-
response curve for con-R was generated to obtain an IC50
value for the NR1-3b/NR2D subtype using the present
protocol (see Table 2).
The concentration-response curves for the chimeric
and parent peptides are shown in Figure 4. As expected,
con-Rdiscriminated heavily against theNR2D subunit in
favor of NR2B (Figure 4B), whereas con-Br did not
(Figure 4A). Con-R/Br showed selectivity that favors
NR2B, in a fashion similar to that of con-R
(Figure 4D). Con-Br/R discriminated much more weakly
between the NR2B and NR2D, more closely resembling
the selectivity of con-Br (Figure 4C). Interestingly, both
analogues were far less potent on both receptor subtypes
than the parent peptides (Table 2). The IC50 ratios for
NR2D/NR2Bof con-Br and con-Br/R are approximately
equal (∼2-3), while the corresponding ratios of con-R
and con-R/Br are also similar (>30). These results sug-
gest that one or more N-terminal residues in con-Br are
responsible for the lack of discrimination between NR2B
and NR2D.
Localization of Key Amino Acid Residues Important for
Subtype Selectivity. To further localize key N-terminal
amino acid determinants for subtype selectivity, we
synthesized six con-R and con-Br variants, in which
groups of 1-4 amino acids at differing N-terminal se-
quence positions of one peptide were replaced with the
amino acids from the corresponding regions of the other
peptide (see Table 3). The subtype selectivity of these
analogues with respect toNR1-3b/NR2B andNR1-3b/
NR2D was assessed. Variants in which the middle amino
Table 1: Comparison of Predicted Mature Con-Br Sequence with Other Conantokinsa
conus species conantokin amino-acid sequence ref
C. brettinghami con-Br GD γγ YS K FI γ RER γ AGRLDLSKFP∧ this work
C. purpurascens con-P GE γγ HS K YQ γ CLR γ IRVNKVQQγC (∧) 24
C. parius con-Pr1 GE Dγ YA γ GIR γ YQL I HGKI∧ 25
C. parius con-Pr2 DE Oγ YA γ AIR γ YQL K YGKI∧ 25
C. parius con-Pr3 GE Oγ VA KWA γ GLR γ KASSN* 25
C. radiatus con-R GE γγ VA KMAA γ LAR γ NIAKGCKVNCYP∧ 28
C. lynceus con-L GE γγ VA KMAA γ LAR γ DAVN* 26
C. tulipa con-T GE γγ YQ KML γ NLR γ AEVKKNA* 20
C. geographus con-G GE γγ LQ γ NQ γ LIR γ KSN* 27
a ∧= COOH; * = CONH2.
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acids were replaced (R [Br 7-9] and Br [R 7-10]) were
rendered inactive or greatly diminished in potency
(Figure 5A-B). Substituting the amino acids from posi-
tions 5-6 of con-Br into the corresponding regions of
con-R resulted in a peptide with activity similar to that of
con-R with respect to NR2B but a 3-fold increase in
potency for NR2D (Figure 5C and Table 2). In the
context of con-Br, replacing residues at positions 5-6
with those in con-R led to a decrease in activity on both
receptor subtypes but with a 10-fold relative increase in
selectivity toward NR2B (Figure 5D and Table 2). These
data suggest that one or both residues at positions 5-6 of
both peptides are important for determining selectivity
among these receptor subtypes.
Two recently characterized conantokins fromC. parius
(con-Pr1 and con-Pr2) with relatively high affinities for
NR2Dhave a tyrosine at sequence position 5 (25), sharing
conserved sequence homology with con-Br (see Table 1).
We therefore examined the role of the con-R and con-Br
amino acids at position 5 with respect to NR2B-NR2D
subtype selectivity. In the context of con-R, replacing the
valine at position 5with tyrosine resulted in a peptidewith
an NR2B potency equal to that of con-R and a 3-fold
increase in potency for NR2D, indicating that the amino
FIGURE 3: NMDA receptor current traces in the presence and absence of con-Br. (A) Left: NR2B current elicited by agonist pulse before and
after buffer control. Right: baseline NR2B response followed by current elicited following a 10 min application of 1 μM con-Br. (B) Effects of
buffer control (left) and 1 μM con-Br (right) on NR2D.
Table 2: Approximate IC50 Values of Con-Br, Con-R, and Analogues
peptide NR2A IC50 (μM) NR2B IC50 (μM) NR2C IC50 (μM) NR2D IC50 (μM) NR2D/ NR2B IC50 ratio
con-Br 0.68 0.14 4.9 0.31 2.2
con-R 0.53 0.35 ∼10 >10 >30
Br/R 2 5.5 2.75
R/Br 3.7 >100a >30a
Br [R 5-6] 5.2 >100 >20
R [Br 5-6] 0.40 3.1 7.8
Br [Y5V] 3.3 >100 >30
R [V5Y] 0.35 3.4 9.7
aPredicted values are based on curve fit (see Materials and Methods).
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acid at position 5 is a significant determinant of the
subtype selectivity seen in R [Br5-6] (Figure 6E and
Table 2). Replacing the tyrosine in con-Br with a valine
resulted in a 20-fold decrease in potency for NR2B
(Figure 6F and Table 2). Despite this marked decrease
in potency, however, this single amino acid substitution
dramatically shifted the selectivity of con-Br toward
NR2B, resulting in a NR2D/NR2B IC50 ratio similar to
that seen in con-R (see Table 2). The shifts in selectivity
profiles of the two position 5 variants suggest that the
amino acid at this position is a key determinant of NR2B-
NR2D selectivity.
Molecular Modeling. A characteristic feature of con-
antokins is their helical conformation stabilized by inter-
actions of Gla residues with divalent cations (31, 46, 50).
Modeling of two linear conantokins, con-Br and the
con-R/Br chimera, was performed using the NMRmodel
of con-T, as described in the Materials and Methods
section. Con-Br and the chimera exhibited a substantial
amount of helical conformation (Figure S1, Supporting
Information) that was further confirmed using the sec-
ondary structure prediction program, PSIPRED (37, 51)
(Figure S2, Supporting Information). To better charac-
terize conformational properties of con-Br and con-R/Br,
the initial model structures containing Mg2+ cations
(used as counterions to neutralize the charge and solvated
by the explicit water model) were submitted to molecular
dynamics analysis. The MD results are summarized in
Figure 6 and Tables S2 and S3 (Supporting Information).
Figure 6 shows the superimposition of five averaged
structures of con-Br and con-R/Br generated from 1.25 ns
MD run with 250 ps frequency. The results of the MD
simulations confirmed that the helical structure between
residues 2-13 is dominant for both conantokins. The
helical structure is particularly pronounced in con-Br
between residues 2 and 12 and for the con-R/Br chimera
between residues 2-13 with three additional residues
(17-19) forming a short helical fragment. From the
superimposition, we are able to observe that the confor-
mation of the con-R/Br chimera is somewhat less stable in
an aqueous environment than con-Br. However, the
structure of con-Br is very stable during the MD simula-
tion. In both cases, the helical motif is present between
residues 2-13. To measure the stability of the conforma-
tions, we calculated the rms value duringMD simulations
for both conantokins as well as for the selected helical
region between residues 2-13 (Figure 6C). It is notable
FIGURE 4: NR2B and NR2D discrimination of con-Br, con-R, and chimeras. (A) Concentration-response curves for con-Br on NR1-3b/
NR2B andNR1-3b/NR2D, showing weak discrimination between the two subtypes. (B) Con-R concentration-response curves for NR2B and
NR2D, showing high selectivity toward NR2B. (C) Br/R concentration-response curves for NR2B and NR2D. (D) R/Br concentration-
response curves for NR2B and NR2D. R/Br and Br/R sequences are shown in Table 3.
Table 3: Amino Acid Sequences of Con-Br and Con-R Variantsa
peptide name amino-acid sequence
con-Br GD γγ YS K FI γ RER γ AGRLDLSKFP
con-R GE γγ VA KMAA γ LAR γ NIAKGCKVNCYP
Br/R GD γγ YS K FI γ LAR γ NIAKGCKVNCYP
R/Br GE γγ VA KMAA γ RER γ AGRLDLSKFP
con-Br [R7-10] GD γγ YS KMAA γ RER γ AGRLDLSKFP
con-R [Br7-9] GE γγ VA K FI γ LAR γ NIAKGCKVNCYP
con-Br [R5-6] GD γγ VA K FI γ RER γ AGRLDLSKFP
con-R [Br5-6] GE γγ YS KMAA γ LAR γ NIAKGCKVNCYP
con-Br [Y5V] GD γγ VS K FI γ RER γ AGRLDLSKFP
con-R [V5Y] GE γγ YA KMAA γ LAR γ NIAKGCKVNCYP
aAmino acid substitutions are shown in bold.
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that the calculated values of the rmsd are lower for the
calculation of the helical region, suggesting that the
helices stabilize the structure of the peptides.
DISCUSSION
In this work, we characterized con-Br, a conantokin
peptide from a species not previously analyzed, Conus
brettinghami. A comparison of the sequence of con-Br
to known conantokins is shown in Table 1. One functional
difference between conantokin-Br and previously charac-
terized conantokins is the relatively high potency for
NMDA receptors that have an NR2D subunit. All con-
antokins characterized so far have a preference for NR2B;
presumably the relevant target in the fish prey of these
piscivorous species is an NMDA receptor complex with a
subunit similar to that of the mammalian NR2B subtypes.
However, the relative affinities for other NMDA receptor
subtypes vary, and conantokin-Br is noteworthy in the
relatively high potency for NR2D containing NMDA
receptor complexes. In contrast, con-R has low potency
(>10um) for the NR2D subtype.
We used the differential affinities of conantokin-Br and
conantokin-R for the NR2D subunit to evaluate chimeras
and analogues of conantokin-Br and conantokin-R for
activity on NMDA receptors containing the NR2B and
NR2D subunits. When chimeras were made of conanto-
kin-Br and conantokin-R, both of the resulting chimeras
had a significantly lowered potency for both NMDA
receptor subtypes, compared to the native parent peptides.
However, even at the lower affinities, the ratio between
FIGURE 5: Relative inhibitory potencies of con-Br and con-R variants onNR1-3b/NR2B andNR1-3b/NR2D.Con-R [Br 7-9] and con-Br [R
7-10] have greatly reducedpotency onNR2BandNR2D(A,B).Con-R [Br 5-6] and con-R [V5Y] retain their potency onNR2Banddiscriminate
less strongly against NR2D (C,E). Con-Br [R 5-6] and con-Br [Y5V] have reduced potency on both subtypes and discriminate strongly against
NR2D (D,F). Sequences of con-Br and con-R variants are shown in Table 3.
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NR2B and NR2D differed between the chimeras; only the
chimera with the N-terminal half of con-Br showed a
comparable potency for NR2D and NR2B, while the
chimera with the N-terminal half of con-R showed a
∼30-fold lower potency for NR2D compared to that of
NR2B.These results suggest that despite the fall in potency
for both receptor subtypes, there were determinants for
differential binding to NR2D in the N-terminal region. A
residue switch at position 5 between con-Br and con-Rwas
particularly revealing. In (V5Y) con-R, the potency of the
peptide for the NR2B subtype was not significantly per-
turbed, but a higher potency for NR2D subtype was
observed. This result suggests that the presence of tyrosine
in con-Br contributes to its higher potency for the NR2D
subtype, although there may be other determinants that
further improve the potency for this subtype that remain to
be identified. To this end, we also synthesized a chimeric
peptide to test the role of Asp at position 2 in con-Br, the
other likely determinant of selectivity; however, the data
suggest that this is not a significant determinant of NR2D
selectivity (not shown). The reciprocal analogue, (Y5V)
con-Br had very poor relative potency for NR2D, thus
confirming that position 5 is an important determinant of
NR2D selectivity; however, this single residue substitution
also lowered the potency forNR2Bapproximately 20-fold,
suggesting that it had lower binding energy for shared sites
in both the NR2B and NR2D subtypes. Interestingly, the
amino acid at position 5 has been shown to be essential for
activity in conantokin-T (48) and is a key determinant of
NR2A-NR2B selectivity in conantokin-G (49). Further-
more, all native conantokins that have a tyrosine at
position 5 have a relatively higher potency for NR2D
(see ref 25). Thus, the residue at this position may be
partially predictive of the subunit selectivity of a given
conantokin.
From the data included in thiswork, it cannot be directly
ruled out that the C-terminal disulfide loop in con-R
analogues may confer properties that govern peptide
activity and subunit selectivity. Several lines of evidence
suggest this possibility is highly unlikely, however. First,
earlier structure function studies of con-R using circular
dichroism analysis and [3H]MK-801 binding displacement
assays suggest that structure and NMDA receptor activity
are virtually unchanged in C-terminal truncation variants
comprising the first 17 amino acids of con-R, which
exclude the C-terminal disulfide bond (47, 52). Second,
unpublished data from our recent characterization of
con-P, which contains an unusually long disulfide
loop, (24) shows similar activity and subunit selectivity in
both reduced alkylated and oxidized forms, indicating that
the disulfide bond plays little or no role in the NMDA
antagonist activity of the peptide. Finally, extensive struc-
ture-activity studies of con-G and con-T, in addition to
con-R (reviewed in ref 31), and the data in this work,
FIGURE 6: Molecularmodeling of con-Br and con-R/Br. Ribbon representation of con-Br (A) and con-R/Br chimera (B). Superimposion of five
averaged structures generatedwitha frequencyof 250ps froma1.25nsMDsimulation run. (C) rmsdeviation for conantokins con-Br and the con-
R/Br chimera calculated during the MD simulation for each residue (all atoms were included). rms deviation was also calculated for the chosen
helical region, which included residues 2-13 for both peptides.
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suggest that structural properties important for peptide
activity are conferred by the N-terminal amino acids of
the peptide.
From the discovery of the first conantokins and the
presence of γ-carboxyglutamate residues in these peptides,
combined with the similarity in the spacing of the Gla
residues to the Gla domains of mammalian blood-clotting
factors, it was immediately hypothesized that these
peptides assumed a helical structure stabilized by Gla
residues chelated to Ca2+ or other divalent cations. This
has been strongly supported by a variety of NMR studies
(31, 46, 50, 53). Molecular modeling and MD studies on
con-Br and con-R/Br confirmed substantial amount of the
R-helical conformation in the N-terminal parts of the
peptides. The data obtained here also suggest that the
conantokin framework of Gla residues should not be
regarded as a rigid helical scaffold from which side chains
are displayed that can interact with partner residues on
their specificNMDAreceptor targets. Such amodelworks
reasonably well for the (V5Y) con-R analogue: the sub-
stitution of Tyr for Val clearly increases the potency of
conantokin-R for theNR2Dsubunit,without a large effect
on the potency for the NR2B subunit. However, in most
other chimeras or substitutions, the significant decrease in
potency observed for the different NMDA subunits tested
indicate that the potency of conantokins for particular
NMDA receptors is a more subtle function of the entire
structure; the nonreciprocal nature of the complementary
substitutions at position 5 of con-R and con-Br in terms of
NR2B potency emphasize this general perception.
Although differences in selectivity uncovered so far are
modest, the lack of subtype selective NMDA receptor
ligands makes the development and further exploration of
the conantokin family highlydesirable.The conantokins are
widespread acrossConus, and clearly, the concerted discov-
ery strategy used for other families of Conus peptides
(29, 54) gives grounds for optimism that a broader survey
of the conantokin gene family across the entire phylogenetic
range of cone snails may yield novel conantokin peptides
and their derivatives that will prove useful for identifying
additional determinants of subtype selectivity. The first step
inbeing able to efficiently scan a libraryofnatural sequences
for potentially novel-targeting specificity is to have informa-
tion regarding which residues may be selectivity determi-
nants; the work that we have described in this article is
a significant step in this important direction.
It is highly desirable to continue developing NR2D
specific ligands. The NR2D subunit confers a number of
physiologically distinct properties to NMDA receptor
complexes, including low sensitivity to Mg2+ block, resis-
tance to H+ block, and prolonged deactivation kinetics
(reviewed in ref 12), which may make neurons expressing
this subunit particularly vulnerable to excitotoxicity. In
addition, expression of the NR2D subunit is more region-
ally restricted within the brain than NR2A or NR2B
subunits, with expression primarily localized to the dien-
cephalons and midbrain (34), and an enrichment of ex-
pression in the substantia nigra and striatum (55, 56).
Thus, the development of an NR2D-specific ligand may
help to evaluate the role of thisNMDAreceptor subtype in
a number of pathological conditions affecting these
regions, such as Parkinson’s disease.
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CONANTOKIN-R AND CONANTOKINRL-B DISCRIMINATE BETWEEN 
THE NR2B AND NR2D SUBUNITS THROUGH COMMON REGIONS 
IN THE S1 AND S2 SUBDOMAINS OF NR2B 
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Abstract 
Conantokins are peptide antagonists of NMDA receptors derived from the venom of 
marine cone snails.  Conantokins exhibit subtype selectivity depending on the NR2 subunit 
composition present in the NMDA receptor complex.  Here, we describe experiments to identify 
the regions of the NR2D and NR2B subunits important for the differential sensitivity to two 
NR2B-preferring conantokins: Conantokin-R (Con-R) and ConantokinRl-B (ConRl-B).  To this 
end, we designed chimeras of the NR2B and NR2D subunits, heterologously expressed chimeric 
receptor complexes in Xenopus oocytes, and assessed the sensitivities to Con-R and ConRl-B 
using two-electrode voltage clamp electrophysiology.  Our results show that both the S1 and S2 
glutamate-binding subdomains are important for sensitivity to Con-R and ConRl-B, with the C-
terminal regions of S1 and S2 from NR2B yielding the greatest increases in sensitivity upon 
homologous substitution into NR2D.  Evaluation of point mutants shows that two amino acids in 
NR2B, Tyr 507 and Val 510, import the sensitivity of the S1 domain to Con-R when substituted 
for the corresponding residues (Asp 531 and Ile 534) in NR2D.  These amino acid substitutions, 
however, had no effect on sensitivity to ConRl-B or ifenprodil.  The results in this work suggest 
that each conantokin interacts with a distinct set of amino acids on the NR2 subunits to determine 
selectivity. 
Abbreviations are as follows: HPLC, High-Performance Liquid Chromatography; Con, 
Conantokin; NMDA, N-methyl-D-aspartate; NMDAR, N-methyl-D-aspartate receptor; NR1, N-
methyl-D-aspartate receptor subunit 1; NR2, N-methyl-D-aspartate receptor subunit 2, NR3, N-
methyl-D-aspartate receptor subunit 3, NTD, N-terminal domain of NR subunits; S1 and S2, 
extracellular glutamate-binding subdomains 1 and 2, respectively, of NR subunits; TM, 
transmembrane domain of NR subunits; CTD, C-terminal domain of NR subunits; P, Pore-lining 
region of NR subunits; Gla,	  γ-­‐carboxyglutamate 
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Introduction 
N-methyl-D-aspartate receptors (NMDARs) are members of the glutamate receptor 
superfamily of ion channels that have critical function in learning and memory (Morris, 2013), as 
well as an array of neuropathic conditions, such as stroke, epilepsy, and chronic pain (Meldrum, 
1994; Childers et al., 2007; Gonda, 2012).  A large diversity of genes encoding NMDA receptor 
subunits have been identified, with one NR1 gene (with eight splice variants), four NR2 genes, 
and two NR3 genes (Cavara et al., 2008; Hollman and Heinemann, 1994; Matsuda et al., 2002; 
Simeone et al., 2004).  In the nervous system, NMDARs are tetrameric, comprising two NR1 
subunits and a combination of NR2 or NR3 subunits (Schuler et al., 2008; Simeone et al, 2004).   
The given set of NMDA receptor subunit genes can potentially generate a tremendous diversity of 
receptor subtypes.   
As of yet, a set of pharmacological tools capable of targeting individual NMDA receptor 
subtypes with a high degree of specificity has not been assembled.  Ifenprodil and derivatives 
define one class of noncompetitive NMDA receptor antagonist that exhibits high specificity for 
NMDA receptors containing the NR2B subunit (Chenard and Menniti, 1999; Fischer et al., 1997; 
Mosley et al., 2009).  Additionally, some small molecules have been developed that are capable 
of targeting NR2C- and NR2D- containing subtypes with some degree of specificity over those 
containing NR2A or NR2B (Costa et al., 2009; Feng et al., 2004; Mosley et al., 2010). 
Conantokins are a unique group of peptidic NMDA receptor antagonists derived from the 
venom of marine cone snails (genus Conus).  Conantokins are generally selective towards NMDA 
receptors containing the NR2B subunit, but vary in their selectivity towards NMDA receptors 
containing other NR2 subunits (Donevan and McCabe, 2000; Sheng et al., 2007; Twede et al., 
2009a; Twede et al., 2009b).  A number of studies have shown a competitive interaction at the 
glutamate-binding site on the NR2 subunits (Donevan and McCabe, 2000; Hammerland et al., 
1992; Wittekindt et al., 2001).  ConantokinG  (ConG) was found to exhibit a preference for 
NR2B- over NR2A- containing NMDA receptors by interacting with amino acid residues in the 
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S2 subdomain, near the glutamate binding pocket (Sheng et al., 2009).  Whether other 
conantokins interact with NR2 subunits in a similar manner, and whether similar regions are 
important for the differences in selectivity between subunits (e.g., NR2B vs. NR2D or NR2C) is 
not known.   
Conantokin-R (Con-R), is a previously characterized conantokin that is highly potent on 
NR2B-containing NMDA receptors and little affinity for NMDA receptors containing the NR2D 
subunit (Twede et al., 2009; White et al., 2000).  More recently, ConantokinRl-B (ConRl-B) was 
shown to have a high degree of NR2B specificity (Gowd et al., 2012).  Here, we describe 
experiments that identify determinants of sensitivity of NR2B-containing NMDA receptors to 
Con-R and ConRl-B.  Unlike ConG, Con-R and ConRl-B interact with both the S1 and S2 
subdomains to discriminate between NR2B and NR2D. The results described herein comprise 
necessary steps towards the rational design of selective antagonists capable of distinguishing 
among the various NR2 NMDA receptor subtypes. 
 
Materials and methods 
Construction of chimeras. Clones of cDNA encoding rat NR1-b NR2B, and NR2D were 
obtained from Dr. Michael Hollman (Ruhr University, Bochum, Germany).  Chimeric NR2B and 
NR2D subunits were made using standard molecular biology methods.  Figure 3.1 shows the 
approximate regions of substitution for NR2B into NR2D.  Chimera 2 comprised a substitution 
from the N-terminal extracellular domain in NR2D (AAs 1-567) for that of NR2B (AAs 1-543).  
Chimera 4 comprised a substitution of the “S2” subdomain (the extracellular transmembrane 
domain 2-3 linker) from NR2D (AAs 684-823) for the “S2” subdomain of NR2B (AAs 660-799).  
Chimera 5 included both of the substitutions in Chimera 2 and Chimera 4.  Chimera 3 involved 
substitutions at the “S1” subdomain (412-567 NR2D for 390-543 NR2B).  All other chimeric 
constructs involved amino acid substitutions within these regions (see Table 3.1).  All point 
mutants were constructed by site-directed mutagenesis, using a site-directed mutagenesis kit, 
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according to the manufacturer’s protocols (Stratagene, Inc.).  All mutant constructs were 
subcloned into a sp72 vector (Promega, Inc.) for subsequent in vitro transcription, and 
heterologous expression in Xenopus oocytes. 
Heterologous expression of NMDA receptors in Xenopus oocytes.  Rat NMDA receptor 
clones NR2B, NR2D, and NR1-2b were used (GenBank entries U11419, U08260, and U08264,), 
in addition to subunit chimeras using the NR2B and NR2D clones as templates. NR2B, NR2D, 
and subunit chimeras were co-expressed with the NR1-2b subunit.  All expression clones and 
mutant variants were under control of a T7 promoter.   For each clone, Ambion transcription kits 
(Ambion, Inc.) were used to make capped RNA for injection into Xenopus oocytes. To express 
NMDA receptors, 2-5 ng of RNA encoding each subunit was injected into each oocyte.  Oocytes 
were incubated in ND96 solution [96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 
mM HEPES (pH 7.2-7.5) with antibiotics (Gentamicin and Pen/Strep).  All voltage-clamp 
electrophysiology was performed prior to 7 days following injection. 
Electrophysiology.  All oocytes were voltage clamped at -70 mV.  Experiments were 
performed at room temperature, and oocytes were gravity-perfused with Mg2+ free ND96 buffer 
[96.0 mM NaCl, 2.0 mM KCl, 1.8 mM CaCl2, and 5 mM HEPES (pH 7.2-7.5)].  BSA (0.1 
mg/mL) was added to reduce nonspecific absorption of peptides.  Previous work has shown 
similar responses of NMDA receptors expressed in oocytes to conantokins in the presence of 
ND96 containing either calcium or substituted with barium (Gowd et al., 2012).   
The sensitivity to glutamate was assessed for all native and chimera NMDA receptor 
subunit combinations tested.  To determine the response to glutamate, oocytes were administered 
a 20 µL bolus of glutamate combined with saturating (20	  µM)	  glycine perfused in Mg2+ -free 
ND96 buffer.  Glutamate was administered in increasing concentrations until saturating 
concentration, or the concentration at which there was no further increase in current response was 
determined.  All glutamate responses were normalized to the maximum current response 
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(saturating current) for each oocyte. EC50 values were determined using the following equation: 
response = 100/[1+(EC50 /[agonist])nH].    
For experiments assessing the block of heterologously expressed NMDA receptors by 
antagonists, NMDA receptor-mediated current was elicited by 1-second pulses of 200	  µM	  
glutamate and	  20	  µM glycine in Mg2+-free ND96.  Agonist concentrations elicited greater than	  
90% of maximal current in oocytes for all NMDA receptor subtypes tested.  To measure the 
effect of antagonists on oocytes expressing NMDA receptors, the buffer flow was halted, and 
antagonists were applied for a minimum of 5 minutes, or sufficient time to reach equilibrium.  
Inhibition of NMDA receptor-mediated current was measured by normalizing the first response to 
agonist following application of antagonist to the baseline response to agonist.  A virtual 
instrument was used for data acquisition (made by D. Yoshikami, University of Utah).  
Concentration response curves were calculated using Prism software (Graphpad Software, Inc.).  
The following equation was used to fit the concentration response curves: % response = 
100/[1+([peptide]/IC50)nH], where nH is the Hill coefficient, and IC50 is the concentration required 
to achieve half-maximal block. 	  
Peptide synthesis.  Con-R  and ConRl-B were synthesized using standard N-(9-fluorenyl) 
methoxycabonyl (Fmoc)-protected amino acids, in an ABI model 430A peptide synthesizer.  
Synthesis was performed by Dr. Scott Endicott of the DNA/Peptide Facility at the University of 
Utah.  The peptide was cleaved from resin by treatment with 1 mL of a mixture of trifluoroacetic 
acid/H20/1,2-ethanedithiol/phenol/thioanisole (82.5/5/2.5/5/5 by volume).  Peptide was agitated 
in the mixture for 2 hours at room temperature, and the mixture was filtered under vacuum into 
methyl-tert-butyl ether at -10 degrees C.  Peptide was precipitated from the mixture and collected 
by centrifugation at 5000 x g for 5 minutes.  The supernatant was removed, and the pellet was 
washed with methyl-tert-butyl ether and centrifuged twice more.  The pellet was dissolved in 
20% ACN in 0.1% trifluoroacetic acid.  Purification was carried out by High-Performance Liquid 
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Chromatography (HPLC) using a Vydac C18 semipreparative column (10 x 250 mm, 5 mM 
particle size), using a flow rate of 5ml/minute and a gradient of solvent B.   Con-R was 
oxidatively folded in a 1:1 mixture of reduced and oxidized glutathione (1mM each) in a solution 
of 100mM Tris and 0.1mM EDTA.  The folded peptide was purified by HPLC using a Vydac C18 
analytical column (at a flow rate of 1ml/minute) and a gradient of Solvent B. 
Use of other agents for electrophysiology.  Ifenprodil was obtained from Sigma (St 
Louis, MO).  For use in electrophysiology assays, a stock solution of ifenprodil was made by 
dissolving in Dimethyl Sulfoxide (DMSO) at a concentration of 10 mM.  Subsequent dilutions for 
electrophysiology assays were made in Mg2+-free ND96 with BSA. 
	  
Results 
Design of NR2 subunit chimeras.  NR2 subunits of the NMDA receptor comprise 
structural and functional subdomains homologous to those of other genes in the ionotropic 
glutamate receptor family (Dani and Mayer, 1995).   These domains include the extracellular N-
terminal regulatory and glutamate binding subdomains (NTD and S1, respectively), three 
transmembrane (M1-M3) domains, a re-entrant pore loop (P), a second extracellular glutamate 
binding subdomain (S2) and an intracellular C-terminal domain (CTD) (See Figure 3.1).  Studies 
indicate a competitive interaction of conantokins at the glutamate-binding site (S1 and S2 
domains), including shifts in glutamate EC50 values with increasing conantokin concentrations, 
and point mutations in the glutamate binding pocket affecting glutamate binding (i.e., Donevan 
and McCabe, 2000;  Wittekindt et al., 2001; but see Skolnick et al., 1992).   
To determine which regions were most important for the high sensitivity of NR2B and 
corresponding low sensitivity of NR2D to Con-R and ConRl-B, we examined the contribution of 
the extracellular domains (NTD, S1 and S2) of these subunits to the conantokin inhibition.  To 
this end, we made substitutions in specific regions in the DNA encoding the extracellular 
domains of the NR2B and NR2D subunits.  The resulting NMDA receptor subunit variants are 
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termed Chimeras 1-12, along with variants and point mutants.  Domain topologies of Chimeras 2-
9 are shown in Figure 3.1.  We first designed a construct comprising the NTD of NR2D, and the 
remaining NR2 domains of NR2B.  This construct (Chimera 1), however, did not express 
sufficient current to perform our assays when mRNA encoding the subunit was co-injected with 
NR1-b into Xenopus oocytes (<20 nA, not shown).  We next made the converse construct, with 
the N-terminal domain of NR2B, and the remaining domains of NR2D (Chimera 2).  This 
construct yielded much greater current levels upon expression in oocytes (ranging from 500 to 
5000 nA) upon application of saturating concentrations of agonists	  (200 µM glutamate and 20 
µM glycine), sufficient for use in further experiments.   To differentiate between the contribution 
of the NTD and S1 to Con-R sensitivity, we then constructed a chimera containing the NTD of 
NR2D, S1 of NR2B, and the remaining domains of NR2D (Chimera 3).  We also constructed an 
NR2D variant with a substitution of S2 from NR2B (Chimera 4).  Chimeras 6-7 and 8-9 were 
NR2D variants with NR2B substitutions in subregions of Chimeras 4 and 3, respectively.  
Chimeras 10-12, along with all variants and point mutants were constructed as substitutions in 
subregions of Chimera 9, based on the results obtained with functional tests of Chimeras 1-9. 
Similar to Chimera 2, Chimeras 3-12 and all variants yielded sufficient current levels for 
subsequent experiments.	  
Localization of regions important for Con-R sensitivity.  Con-R has a high potency on 
NR2B subtypes, and a low potency on NR2D subtypes (Twede et al., 2009; White et al., 2000).  
Other conantokins, such as ConG, while NR2B selective, typically target NR2D-containing 
NMDA receptor subtypes with much greater potency (Twede et al., 2009). We therefore used 
Con-R as a tool to discriminate between the two subunits and identify regions important for 
conantokin sensitivity.  Figure 3.2A shows the contrast in selectivity profiles of Con-R for NR2B 
and NR2D, co-expressed with NR1-b in Xenopus oocytes.  Con-R has an approximately 30-fold 
higher potency on the NR1-b/NR2B subtype than the NR1-b/NR2D subtype (Twede et al., 2009; 
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also see Table 3.1).   As shown in Figure 3.2B and Table 3.1, the sensitivity of NR2D to Con-R 
was increased to a similar extent (~ 6 fold) by both substitutions in the N-terminal extracellular 
(Chimera 2) and S2 (Chimera 4) domains. The simplest interpretation of this result is that Con-R 
interacts with both the S1 and S2 domains of the NR2B subunit. The amino-terminal domain may 
also contribute to the observed increase in sensitivity, however.  Comparison of Chimera 2 with 
Chimera 3, which differ only in the identity of residues in the NTD, show a relatively minor 
contribution: there was an approximately 2-fold difference between the IC50 values of Chimera 2 
and Chimera 3 (0.81 and 1.7 µM, respectively).  Thus, a subtle shift in sensitivity was observed 
upon substitution of the NTD.  Lastly, the simultaneous substitution of the extracellular NTD, S1, 
and S2  subdomains (Chimera 5) resulted in a sensitivity to Con-R that was equal to that of the 
native NR2B subtype (Table 3.1; Fig. 3.2B), suggesting that these regions completely recapitulate 
the sensitivity of the native NR2B subtype to Con-R.   
Given that the data suggest determinants of sensitivity reside in both S1 and S2, these 
subdomains were divided into substitutions in four subregions so as to construct Chimeras 6 -9, 
that contain more highly localized substitutions (See Figure 3.1).   Interestingly, replacement of 
NR2D residues with NR2B residues in all four subregions enhanced the sensitivity to Con-R 
(Table 3.1, Figure 3.2C).  However, replacements within the C-terminal half of S2 in Chimera 7 
appeared to make a greater contribution to sensitivity than replacements within the N-terminal 
half of S2 in Chimera 6 (9-fold and  4-fold increases, respectively) (Table 3.1, Fig. 3.2C).  More 
surprisingly, the sole substitution of the C-terminal half of NR2B S1 (Chimera 9) completely 
restored the sensitivity to Con-R seen in native NR2B (Table 3.1, Fig. 3.2C). Among the 
constructs, replacements of entire subdomains from NR2B (either NTD, S1 or S2) appeared to be 
additive, reconstituting the sensitivity of the native NR2B subunit when combined (as in Chimera 
5); mutants with smaller substitutions (i.e., Chimeras 6-9), however, did not retain the additivity 
of the parent chimeras (see Table 3.1). 
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Localization of residues important for Con-R sensitivity.  Although the data suggest 
determinants important for sensitivity to Con-R reside in both S1 and S2, the high contribution to 
sensitivity of the C-terminal half of the S1 subdomain led us to investigate this region further.  To 
localize contributing residues, we further subdivided this region into three segments, and the 
resulting sensitivities are shown in Table 3.1 and Figure 3.3.  Of the three substitutions in the C-
terminal half of S1 (Chimeras 10-12), only one (Chimera 11; 7 divergent AAs) had an increase in 
sensitivity to Con-R, suggesting residues in this region were predicted to account for a degree of 
the sensitivity observed in Chimera 9 (Figure 3.3B).  Interestingly, the Con-R IC50 value for 
Chimera 11 (1.9 µM) was more similar to that of Chimera 3 than to that of Chimera 9 (1.7 µM 
and 0.15 µM, respectively).  Therefore, although Chimera 9 had an unusually high sensitivity to 
Con-R, these data suggest residues in this subregion reconstitute the partial sensitivity of the 
NR2B S1 subdomain, rather than the complete sensitivity of the NR2B subunit.  To further verify 
the significance of this subregion in the overall contribution to Con-R sensitivity, we combined 
the seven divergent NR2B residues in Chimera 11 with the entire NR2B S2 subdomain.  The 
resulting construct (Chimera 11 [S2]) had Con-R sensitivity similar to NR2B (0.18 µM, 
compared to 0.14 µM, respectively) (Figure 3.3C).  Lastly, we examined the effects of further 
amino acid substitutions within the Chimera 11 region (Table 3.1).  Of the substitutions made 
within these seven amino acids, the simultaneous replacement of two residues (D531Y and 
I534V) in Chimera 15 appeared to contribute most to Con-R sensitivity (Table 3.1, Figure 3.3C).  
Response of NR2 chimeras to glutamate.  Previous studies have shown that some 
substitutions in the S1 and S2 subdomains of NR2 subunits at or near the glutamate-binding locus 
can potentially affect sensitivity to glutamate-site agonists (Anson et al., 1998; Chen et al., 2004; 
Kinarsky et al., 2005; Maier et al., 2004).  To determine whether replacement of residues in these 
regions alter the response to glutamate, and to verify the appropriate agonist concentrations for 
our assays, each NMDA receptor subunit variant was co-expressed with NR1-b in Xenopus 
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oocytes and the resulting assembled channels were assessed for sensitivity to glutamate using 
two-electrode voltage clamp electrophysiology.  Figure 3.4A shows concentration-response 
curves of glutamate on the native NR2B and NR2D subunit combinations co-expressed with 
NR1-b.  NR2D had a slightly lower glutamate EC50 value (3.7 µM) than NR2B (6.3 µM); 
however, in our assay, this difference was within the margin of error. Examples of glutamate 
concentration-response curves for chimeras are shown in Figure 3.4B.  The EC50 for Chimera 2 
(13.7 µM) was approximately 2-fold higher than the EC50 for NR2B (Table 3.1, Figure 3.4B).  In 
addition, Chimera 15 (with an EC50 of 1.9 µM) was approximately 2-fold more responsive to 
glutamate than NR2D (Figure 3.4B).  All other chimeras or point mutants had EC50 values within 
the margin of error of those for one or both of the native subtypes (Table 3.1).	  
Sensitivity of chimeras to other NR2B-selective antagonists.  Data presented here 
demonstrate that residues imparting sensitivity to Con-R are distributed among several regions of 
the NR2 subunit, including S1 and S2.  To test whether conantokins, as a class of NMDA 
receptor antagonists, generally interact with one or multiple regions we challenged each of the 
chimera receptors with ConRl-B.   ConRl-B is a conantokin recently characterized from the 
species Conus rolani (Gowd et al., 2012) that has a high potency on NR2B subtypes, and shows 
little or no potency on NMDA receptor subtypes containing other NR2 subunits (also, see Figure 
3.5A).   Thus, similar to Con-R, ConRl-B selectively inhibits NR2B over NR2D; however, the 
conantokin from C. rolani diverges considerably from Con-R in selectivity towards other NR2 
subtypes, as well as in amino acid sequence (Gowd et al., 2012).  To determine whether ConRl-B 
interacts with NR2B in a manner similar to Con-R, ConRl-B was assessed for sensitivity towards 
the group of NR2 chimeras that exhibited the highest sensitivity to Con-R when heterologously 
expressed in Xenopus oocytes,.  As shown in Figure 3.5 and summarized in Table 3.2, in a similar 
manner to Con-R, chimeras with C-terminal NR2B substitutions in both subdomains of the 
glutamate binding domain (Chimeras 7 and 9, respectively) resulted in receptors with sensitivity 
	   34	  
to ConRl-B.  However, the simultaneous substitution of the two amino acids  in Chimera 15 
(D531Y and I534V)  that had the greatest effect on sensitivity to Con-R  had no effect on 
sensitivity to ConRl-B (Figure 3.5B and 3.5C).  These data suggest the residues important for 
Con-R inbibition are not identical with those important for ConRl-B.  However, the increased 
sensitivity of Chimeras 7, 9, and 5 also indicate more than one region of the NR2 subunits 
contribute to ConRl-B sensitivity, suggesting a manner of interaction similar to Con-R. 
Ifenprodil, another NR2B selective antagonist, is thought to act noncompetitively with 
glutamate and glycine at the regulatory domain on the N-terminal extracellular domain of the 
NR2B subunit (Karakas et al., 2011; Tsai et al., 2005).  To determine whether there is any 
interaction between the residue substitutions important for sensitivity to Con-R (positions 531 
and 534) and ifenprodil, NR2D [D531Y I534V] was also tested for sensitivity towards 10	  µM 
ifenprodil.  As shown in Figure 3.5D, a Chimera 5, a variant containing the NTD of NR2B was 
blocked by 10	  µM ifenprodil to a similar extent as NR2B, suggesting sensitivity to ifenprodil was 
unchanged.  However, in a manner similar to NR2D, Chimera 15 showed little or no sensitivity to 
10	  µM ifenprodil (Fig. 3.5D), suggesting no interaction between ifenprodil and the S1 residues 
identified as important for inhibition by Con-R.   
	  
Discussion 
Analysis of NR2 subunit chimeras.  In this work we generated a series of NR2B and 
NR2D subunit chimeras to localize the regions important for sensitivity to Con-R and ConRl-B.  
Chimeras were assessed for sensitivity by performing concentration-response assays on 
conantokins for each functional mutant we designed.  We assessed sensitivity across a range of 
concentrations to provide a more complete depiction of conantokin-receptor interactions. 
Chimera studies can potentially be designed so that the functional outcome for a given 
mutant (or set of mutants) falls into one of two categories: loss-of-function effects or gain-of-
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function effects.  In theory, loss-of-function mutations can be interpreted as perturbations of 
interaction sites or subunit structure that negatively affect ligand binding, the gating of the effect 
of ligand, or both.  While these can be accurate interpretations, a potential caveat of perturbation 
effects is that they are not necessarily specific to the ligand or molecule of interest.  Rather, the 
perturbations could indicate a more general loss of function (such as a null mutant in the most 
extreme case).  
Gain-of-function mutations, on the other hand, are likely to indicate specific favorable 
interactions between the mutant subunit and the molecule of interest.  The loss-of-function 
mutants (with respect to Con-R sensitivity) we designed in this study did not yield sufficient 
current for testing.  However, we also chose to focus on gain of function mutants to highlight 
specific favorable interactions between conantokin peptides and the NR2 subunits.  While we do 
not initially draw such a distinction in our data, increases in sensitivity may be attributed to more 
favorable interactions for binding, conformational changes favoring conantokin inhibition, or 
both. 
We anticipated one of two potential outcomes for the gain-of-function mutant tests 
designed in this study: either a single localized region would be important for conantokin 
sensitivity, or determinants of sensitivity would be distributed across multiple regions in S1 and 
S2.  Previous work demonstrated that determinants of ConG sensitivity in NR2B were localized 
to specific residues in the C-terminal region of S2 (Sheng et al., 2009). In our study, mutants with 
NR2B substitutions in both S1 and S2 had gain of function effects when compared to NR2D, 
indicating a plurality of potential regions of interaction for Con-R and ConRl-B.   
A number of larger substitutions had increases in sensitivity that could be combined to 
comprise the whole, additionally indicating that multiple regions are necessary for complete 
sensitivity.  For instance, the NR2B-to-NR2D IC50 ratios of Chimeras 2, and 4 could be 
multiplied to comprise the sensitivity of Chimera 5. Furthermore, additivity was suggested by 
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comparison of Chimera 5 (containing all the substitutions of Chimeras 2-4) and native NR2B, 
which were similar in Con-R IC50 value.   
Notably, some smaller substitutions did not retain the additive properties of the whole-
domain NR2B substitutions.  The sensitivity ratios of Chimeras 6 and 7 combine to a total that is 
greater than that of Chimera 4, for instance.  While it is possible that this effect may be simply 
due to random perturbations in protein structure associated with the mutations, the data are 
suggestive of another interpretation: redundant sets of interactions may occur between 
conantokins and the NR2 subunits.  To illustrate, if a particular set of interactions is removed by a 
mutation, another set may be strengthened or replaced upon removal of the prior set. In support of 
this interpretation, it is notable that, in addition to Chimeras 6 and 7, the Con-R sensitivity ratios 
Chimeras 8 and 9 can be multiplied to yield greater sensitivity ratios that those of the parent 
construct, Chimera 3.  Thus, the redundancy effect is observed for multiple mutants.  If this non-
additive effect were simply due to changes in conformation as a consequence of random chance, 
increases in sensitivity (and corresponding super-additive properties) among all four mutants 
would be extremely unlikely.  In contrast, random perturbation effects would predict mutants that 
were less than additive to the whole. In our mutants, nonadditivity was not seen upon substitution 
of the entire S1 and S2 regions, and was only evident in smaller substitutions, as the contacts for a 
given lobe are being disrupted.  Thus, our data predict redundant interactions on the N- and C- 
terminal regions of both S1 and S2. 
Does Con-R discriminate between subunits via multiple sites?  Our data suggest 
determinants of conantokin sensitivity are distributed across multiple regions of the NR2 subunit.  
One potential interpretation of these data is that conantokins distinguish between NMDA receptor 
subtypes via multiple binding sites, suggesting interactions distal from the glutamate-binding site.  
Studies have confirmed a competitive interaction between conantokins (such as ConG) and the 
glutamate-binding site on the NR2 subunits (Donevan and McCabe 2000), while some work has 
suggested a possible interaction between conantokins and the polyamine-binding site on the N-
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terminal domain (Skolnick et al., 1992). Other studies have shown that ConG has biphasic effects 
on NR2A subunits when coexpressed with certain NR1 splice variants (Ragnarsson et al., 2006), 
further suggesting the possibility of additional binding sites.  Our data confirm the importance of 
the S1 and S2 glutamate binding subdomains in conantokin inhibition.  Interestingly, Chimera 2 
showed a 2-fold higher sensitivity to Con-R than Chimera 3, also suggesting a possibility for 
interactions distal to the glutamate-binding site. The majority of the (30- and 100- fold, 
respective) differences in sensitivity to Con-R and ConRl-B, however, were attributed to 
substitutions in the S1 and S2 regions.  Thus, our data localize the major determinants for 
sensitivity to Con-R and ConRl-B as proximal to the glutamate-binding site. 
Conantokin interactions at the glutamate-binding site.  The work presented in this study 
identifies novel residues Tyr 507 and Ile 510 on the NR2B subunit (corresponding to NR2D 
residues Asp 531 and Val 534) as important for Conantokin-R sensitivity. Interestingly, previous 
work has localized residues in the glutamate binding pocket affecting conG sensitivity that are 
conserved across all four NR2 subunits (Wittekindt et al., 2001), while other work has shown that 
residues at positions affecting conG NR2A and NR2B discrimination are conserved among three 
(2B, 2C, and 2D) of the four NR2 subunits (Sheng et al., 2009). As all residues at positions 
previously identified as important for conantokin sensitivity are identical between the NR2B and 
NR2D subunits (Sheng et al., 2009; Wittekindt et al., 2001), the amino acids important for the 
differential sensitivity to Con-R were, by exclusion, predicted to be novel. 
It is noteworthy that the conantokin-sensitive residues we identified had relatively small 
effects on response to glutamate upon substitution (~2-fold or less).  Previous work has shown 
some residues important for conantokin sensitivity greatly affected glutamate binding, whereas 
others had no effect on response to glutamate (Sheng et al., 2009; Wittekindt et al., 2001).  In 
particular, the amino acids conserved across all four NR2 subunits appeared to affect glutamate 
response (Wittekind et al., 2001), while divergent residues had lesser effects on glutamate 
sensitivity (Sheng et al., 2009).  The effect of nonconserved NR2 residue substitutions on 
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differential conantokin sensitivity identified in this, and other studies, suggests that residues 
critical for conantokin activity may be at conserved sites, while the determinants of 
discrimination among the NR2 subunits may be at positions distinct from those involved in 
glutamate binding.  Indeed, previous data have localized the glutamate-binding residues at sites 
distinct from NR2B positions 507 and 510 (Laube et al., 1997). 
In parallel with studies of NMDA receptor subunits, structure-activity studies of 
characterized conantokins also indicate that conserved residues at certain positions are critical for 
activity, whereas other residues are more important for selectivity among the NR2 subunits.  For 
instance, conserved N-terminal residues, including glutamate or aspartate at position 2, appear to 
be critical for conantokin activity (Blandl et al., 2001), while other amino acid positions, such as 
Val 5 in Con-R and Lys 8 in ConRl-B, appear to be critical for selecting among the individual 
NR2 subunits (Twede et al., 2009; Gowd et al., 2012).  
When combined, these findings seemingly argue for conserved points of interaction 
common to both conantokins and NR2 subunits.  In particular, they argue for a “core” binding 
region overlapping the glutamate-binding site, resulting in the observed competitive effect of 
conantokins.  Indeed, docking studies also suggest interactions between the highly conserved 
residue at position 2 in ConG, and conserved residues in the glutamate binding pocket 
(Wittekindt et al., 2001). However, in addition, the data seem to indicate a nonidentical set of 
interactions for each conantokin-subunit combination, resulting in differential selectivity profiles 
among the various conantokins. Interestingly, the double substitution D531Y and I534V in the 
NR2D subunit had no effect on ConRl-B sensitivity, further suggesting a distinct set of 
interactions governs the selectivity for each conantokin.  
Conservation of NR2 subunits and implications for developing selective conantokins.  We 
generated chimeras for this study using NMDA receptor subunit gene clones from rat; however, a 
sequence analysis shows NR2B Tyr507 and Val 510 (along with NR2D Asp531 and Ile534) are 
conserved across the rat, mouse, and human species.  Thus, we predict similar ConR subtype 
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selectivity among these species.  Analysis of the NMDA receptor subunit sequences in zebrafish, 
however, shows differences in amino acids at these homologous positions.  In mammalian 
receptors, conantokins generally target the NR2B subunit with the greatest potency.  As 
conantokins presumably evolved to target fish as prey, the effects and targeting specificity of 
conantokins on fish NMDA receptor subtypes is another question that remains to be addressed.  It 
is interesting to note, however, that the NR2B subunit undergoes significant developmental 
changes in expression, similar to mammalian species (Cox et al., 2005). 
Our findings have implications for the potential development of selective conantokin 
analogs.  These data suggest that conantokins interact with similar regions, but with distinct sets 
of amino acids for each conantokin.  If the core binding site hypothesis is correct, and a distinct 
set of binding interactions is conserved across conantokins and NMDA receptor NR2 subunits, 
this necessarily narrows our search for points of interaction that govern selectivity to residues 
beyond the core binding site.  A solved NR2B structure will facilitate endeavors to develop 
antagonists capable of discriminating among the various NR2 subunits. 
Summary.  The objective of this study was to elucidate the regions of the NR2B and 
NR2D subunits important for the high sensitivity of NR2B and low sensitivity of NR2D to Con-R 
and ConRl-B.  To localize these regions, we designed chimeric NR2B and NR2D subunits in 
order to isolate the sequence components of NR2B that could confer Con-R and ConRl-B 
sensitivity to the insensitive NR2D subunit when substituted into homologous regions.  Our 
major findings were that the C-terminal regions of both the S1 and S2 domains are important for 
sensitivity to both Con-R and ConRl-B.  We also identified two NR2B residues, Tyr 507 and Val 
510, that recapitulate the entire sensitivity of the NR2B S1 region when substituted for the 
corresponding residues in NR2D (Asp 531 and Ile 534).  Our data suggest that, although key 
residues were identified (i.e., those at positions 531 and 534 in NR2D) multiple residues on the 
S1 and S2 domains are involved in the discrimination among subunits.  The data in this study 
suggest that, while Con-R and ConRl-B interact with similar regions in the glutamate binding 
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domains, the two peptides interact with a different set of individual amino acids. Taken together, 
these data suggest that each conantokin may competitively bind at the glutamate site, while 
contacting distinct residues outside the binding pocket to govern individual selectivity.  Further 
work defining how conantokins interact with the individual NR2 subunits could lead to the 




	   41	  






Amino	  Acids	  Changeda	   Glutamate	  
EC50	  (µM;	  
95%CI)	  






NR2B	   -­‐-­‐	   6.3	  (4.8-­‐8.4)	   0.14	  (0.11-­‐0.18)	   -­‐1.51	   36.4	  
NR2D	   -­‐-­‐	   3.7	  (2.7-­‐5.0)	   5.1	  (3.9-­‐6.5)	   -­‐0.75	   1	  
Ch2	   1-­‐567D	  	  à	  1-­‐543B	  	   13.7	  (12-­‐16)	   0.81	  (.71-­‐.92)	   -­‐1.21	   6.17	  
Ch3	   412-­‐567D	  	  à	  390-­‐543B	  	   5.3	  (3.8-­‐7.4)	   1.7	  (1.2-­‐2.5)	   -­‐0.74	   2.9	  
Ch4	   684-­‐823D	  	  à	  660-­‐799B	  	   6.4	  (4.4-­‐9.1)	   0.88	  (.55-­‐1.4)	   -­‐0.94	   5.7	  
Ch5	   1-­‐567D	  à	  1-­‐543B	  
684-­‐823D	  à	  390-­‐543B	  	  
6.3	  (4.5-­‐8.9)	   0.14	  (.12-­‐.17)	   -­‐1.33	   35.7	  
Ch6	   684-­‐747D	  	  à	  660-­‐723B	  	   3.7	  (2.9-­‐4.8)	   1.2	  (1.0-­‐1.5)	   -­‐1.11	   4.2	  
Ch7	   748-­‐823D	  	  à	  724-­‐799B	  	   3.0	  (2.2-­‐4.0)	   0.56	  (.42-­‐.74)	   -­‐1.00	   8.9	  
Ch8	   412-­‐490D	  	  à	  390-­‐467B	  	   8.1	  (6.9-­‐9.6)	   1.3	  (.92-­‐1.9)	   -­‐0.82	   3.8	  
Ch9	   491-­‐567D	  	  à	  467-­‐543B	  	  	   5.4	  (4.5-­‐6.6)	   0.15	  (.11-­‐.22)	   -­‐0.95	   33.3	  
Ch10	   491-­‐500D	  	  à	  467-­‐476B	  	   3.4	  (2.5-­‐4.5)	   5.7	  (2.8-­‐12)	   -­‐0.70	   0.87	  
Ch11	   501-­‐540D	  	  à	  477-­‐516B	  	  	   2.7	  (2.3-­‐3.3)	   1.9	  (1.4-­‐2.6)	   -­‐0.84	   2.6	  
Ch11	  S2	   501-­‐540D	  à	  477-­‐516B	  
684-­‐823D	  à	  660-­‐799B	  	  
2.2	  (2.7-­‐3.5)	   0.18	  (.13-­‐.25)	   -­‐1.03	   27.8	  
Ch12	   541-­‐567D	  	  à	  517-­‐543B	   5.8	  (5.3-­‐6.4)	   9.5	  (6.1-­‐15)	   -­‐0.72	   0.52	  
Ch13 D515D	  àN	  
V517D	  à	  T	  
4.9	  (3.9-­‐6.1)	   2.9	  (2.3-­‐3.7)	   -­‐0.59	   1.7	  
Ch14 F526D	  à	  V	  
Y527D	  à	  M	  
Q528D	  à	  K	  
3.1	  (2.7-­‐3.5)	   10	  (7.5-­‐14)	   -­‐1.10	   .5	  
Ch15	   D531D	  à	  Y	  
I534D	  à	  V	  
1.9	  (1.5-­‐2.4)	   0.99	  (.60-­‐1.6)	   -­‐0.81	   5.1	  
NR2D	  
[D531Y] 
D531D	  à	  Y	  
	  
5.9	  (4.5-­‐7.7)	   2.9	  (2.4-­‐3.5)	   -­‐0.72	   1.7	  
	  
n>3 oocytes tested for each EC50 and IC50 value 
a Corresponding NR2B and NR2D residues shown; NR2B substitutions were made into NR2D 
background. 
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10µM	  /	  NMDAR	  IC50	  
NR2B	   0.1	  (0.08-­‐0.12)	   -­‐1.49	   100	  
NR2D	   >10	   -­‐-­‐	   ~1	  
Ch	  5	   0.04	  (0.03-­‐0.05)	   -­‐1.17	   250	  
Ch	  7	   0.66	  (0.39-­‐1.1)	   -­‐0.77	   15.2	  
Ch	  9	   0.36	  (0.29-­‐0.45)	   -­‐1.38	   27.8	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  |	  
Gene/Construct	   NTD	   S1	   M1	   P	   M2	   S2	   M3	   CTD	   Divergent	  
AAs	  	  
NR2D	   	   0	  
	  
NR2B	   	   941	  
	  
Chimera	  2	   	   	   334	  
	  
Chimera	  4	   	   	   	   40	  
	  
Chimera	  5	   	   	   	   	   374	  
	  
Chimera	  6	   	   	   	   	   23	  
	  
Chimera	  7	   	   	   	   	   17	  
	  
Chimera	  3	   	   	   	   59	  
	  
Chimera	  8	   	   	   	   	   41	  
	  
Chimera	  9	   	   	   	   	   18	  
 
 
Figure 3.1.  Domain topologies of NR2B and NR2D constructs. NR2B regions are shaded in gray 
and NR2D regions are in white.  NTD, N-terminal domain ; S1, Extracellular glutamate binding 
domain1; M1, transmembrane domain 1; P, pore-lining domain; M2, transmembrane domain 2; 
S2, Extracellular glutamate binding domain 2; M3, transmembrane domain 3; CTD, C-terminal 
domain.  Regions substituted in this study are highlighted in bold.  Numbers of residues that 
diverge from NR2D for each variant are shown in the column to the right.  Numbering scheme at 
the top indicate amino acid positions of defined regions in the NR2D subunit. 
 








Figure 3.2.  Both S1 and S2 are important for sensitivity to Con-R.  Concentration response 
curves shown for Con-R on NR1-b coexpressed with native NR2 subunits (A), extracellular 
domain chimeras (B), and S1/S2 subregion chimeras (C) in Xenopus oocytes (n=3-7 oocytes for 
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Figure 3.3. Residues in the C-terminal half of S1 contribute to Con-R sensitivity. (A) Alignment 
of amino acid residues in the C-terminal half of S1.  Divergent residues are highlighted (NR2D) 
or underlined (NR2B).  Black bars indicate regions of subdivision for Chimera 10, Chimera 11, 
and Chimera 12.  In all three regions, divergent NR2B residues were substituted into homologous 
regions of NR2D.  Stars indicate the residues that contributed the greatest to sensitivity upon 
substitution.  (B) Comparison of IC50 values for chimera 9, 10, 11, and 12.  (C) Comparison of 
Chimera 11 and variants that significantly contributed to sensitivity.  Error bars represent 95% 













Figure 3.4.  Effect of NR2B substitutions on glutamate sensitivity.  Glutamate concentration-
response curves for NR1-b coexpressed with native NR2 subunits (A) and selected NR2 mutants 
(B) in Xenopus oocytes (n=3-6 oocytes for each concentration and subtype; error bars represent 
SEM). Dotted line indicates glutamate concentration used in antagonist sensitivity assays. 
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Figure 3.5. NR2B regions important for sensitivity to ConRl-B.  Concentration response curves 
shown for ConRl-B on NR1-b coexpressed with native NR2 subunits (A), or chimeras (B). n=3- 
oocytes per concentration and subtype; error bars represent SEM.  (C) Comparison of 
approximate ConRl-B IC50 values for native receptors and chimeras.  IC50 values for NR2D and 
Chimera 15 are estimated at 10	  µM.  Error bars represent 95% CI.  (D) Sensitivity of native 
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Abstract 
Previously, we functionally fingerprinted peripheral nervous-system neurons through 
pharmacologically intensive calcium-imaging experiments that we call “Constellation 
Pharmacology.” Here, we extend Constellation Pharmacology to the central nervous system, 
demonstrating broad applicability to all nervous system loci. We functionally fingerprinted 
dissociated cells from the ventral respiratory column (VRC) of mouse brainstem, revealing three 
major cell classes, each comprising minor subclasses. One minor neuronal subclass of Class B 
cells responded to substance P, putatively corresponding to inspiratory neurons of the pre-
Bötzinger complex (preBötC) that control breathing patterns.  Among the three classes, 
differences were further identified in expression of Glutamate receptors, including a distinction 
between NR2B subunit-containing NMDA receptor subtypes in Class A cells, and non-NR2B-
containing NMDA receptor subtypes in Class B cells.  Future studies can determine whether 
distinct NMDA receptor subtypes functionally mediate fundamental neuronal processes important 
for the control of respiration in the VRC.  
 
Introduction 
Progress in understanding the mammalian brain has been impeded by the extraordinary 
complexity of cell types that comprise the circuitry and the difficulty in bridging different levels 
of integration (Bernard et al., 2009; Franco and Muller, 2013; Nelson et al., 2006; Sugino et al., 
2006).  Systems neuroscientists study the circuitry and high-level functions of the brain, while 
molecular neuroscientists study the molecular components. The large divide between these two 
approaches may be bridged by identifying key characteristics that differentiate neuronal and glial 
cell types in a circuit. Neuronal and glial cell types exhibit functional variation conferred by the 
differential expression of genes encoding critical signaling proteins, such as neurotransmitter 
receptors, transporters, ion channels, etc. Cell-specific combinations of receptor- and ion-channel 
subtypes are functionally coupled to fine tune each neuronal subtype for specific physiological 
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functions. We refer to a cell-specific combination of signaling proteins as a cell-specific 
“constellation” (Teichert et al., 2012). 
 Recently we have demonstrated an experimental strategy that we call Constellation 
Pharmacology to identify neuronal cell types by their by cell-specific constellations of receptors 
and ion channels (Teichert et al., 2012a; Teichert et al, 2012b).  As proof-of-principle, we initially 
demonstrated this experimental strategy with cells of the peripheral nervous system (PNS): 
specifically, dissociated mouse dorsal-root ganglion neurons.  In the present study, we 
demonstrate that Constellation Pharmacology can be extended to the central nervous system 
(CNS) to identify and characterize different neuronal and glial cell types. This report firmly 
establishes the broad applicability of Constellation Pharmacology for profiling cell types within 
the CNS.  
In this report, we have investigated cells from the ventral-respiratory column (VRC) of 
the mouse brainstem. The VRC contains a variety of neurons that are active during either 
inspiratory or expiratory phases of breathing. One key network within the VRC is the pre-
Bötzinger complex (preBötC), which contains the circuitry responsible for generating respiratory 
rhythms (Gray et al., 2010; Ramirez et al., 1998; Smith et al., 1991; Tan et al., 2008).  This 
network of inspiratory neurons is heterogeneous, encompassing neurons with unique 
pharmacological profiles (Gray et al., 1996; Lieske et al., 2000; Pena et al., 2004; Pena and 
Ramirez, 2004; Ramirez et al., 2012).  Moreover, the tissue immediately surrounding the preBötC 
also contains neuronal networks important to cardiovascular control, such as cardiac 
parasympathetic vagal neurons of the nucleus ambiguus and noradrenergic neurons of the A2/C2 
region (Dergacheva et al., 2010; Zanella et al., 2006).  By investigating the cell-specific 
constellations within different cell types in the VRC, we may ultimately integrate molecular and 
systems level data that allow us to differentiate neurons involved in autonomic control, including 
those that play a role in controlling breathing.  
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Using the Constellation-Pharmacology strategy, we have identified three major classes of 
VRC cells, which can be subdivided further into additional cellular subclasses. Through 
Constellation Pharmacology, we probe a heterogeneous culture of dissociated cells with a panel 
of selective pharmacological agents, among other physicochemical perturbations, while we 
simultaneously monitor the individual responses of more than 100 cells by calcium imaging. By 
monitoring the different response phenotypes, we can parse cell populations into major cell 
classes and minor subclasses.  Among other functional markers, we characterize the expression of 
glutamate receptors within the identified cell classes.  In addition, we use the subtype-selective 
NMDA receptor antagonist conantokinRl-B (ConRl-B) to begin to dissect particular NMDA 
receptor subtypes present within the cellular classes of the VRC. The identification of cellular 
subclasses constitutes an essential first step towards unraveling the physiological roles of these 
cells in future studies. 
 
Materials and methods 
Preparation of solutions.  The medium for culturing VRC neurons, minimal essential 
media (MEM) + supplements, was MEM (Invitrogen) supplemented with 10% (vol/vol) FBS 
(HyClone), penicillin (100 U/mL), streptomycin (100 µg/mL), 1X Glutamax (Invitrogen), 10 mM 
Hepes, and 0.4% (wt/vol) glucose. The medium was adjusted to pH 7.4 with NaOH and then 
filtered through a 0.22-µm filter under sterile conditions. Before use, the medium was stored at 4 
°C. It was allowed to warm to 37 °C in a tissue culture incubator with 5% CO2 atmosphere just 
before use. 
We used artificial cerebrospinal fluid (aCSF) for tissue preparations (brain slices and 
microdissection) and calcium-imaging experiments. It consisted of the following (in mM): 118 
NaCl, 3 KCl, 1.5 CaCl2, 1 MgCl2, 25 sodium bicarbonate, 1 sodium phosphate monobasic, and 30 
glucose. For use in tissue preparations, we bubbled carbogen (95% Oxygen/5% CO2) through the 
aCSF to oxygenate the solution and to adjust its pH to 7.4. For use in calcium-imaging 
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experiments, aCSF was adjusted to pH 7.4 with HCl, and then stored at 4 °C until used in 
calcium-imaging experiments at room temperature.  
All stock solutions of pharmacological agents were stored at −20 °C in small-volume 
aliquots to avoid repetitive freezing and thawing. All working concentrations were obtained by 
diluting stock solutions into aCSF. The following stocks were kept in aqueous solutions, typically 
either physiological saline or water: 2 mM histamine dihydrochloride (Acros Organics), 1 mM 
ATP disodium salt trihydrate (Sigma-Aldrich), 1 M acetylcholine chloride (Sigma-Aldrich), 200 
µM Substance-P (Peptides International), 1 mM Bradykinin, 20 mM Norepinephrine, 3M 
Glutamate (Sigma-Aldrich).  Fura-2-acetoxymethyl ester (Fura-2-AM; Invitrogen) stocks were 1 
mM in DMSO, distributed into single-use aliquots and stored at −20 °C.  
Mouse cell preparations and culture.  The following methods apply to preparation and 
culture of mouse VRC cells. All procedures in this study comply with the rules and regulations in 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were 
approved by the Institutional Animal Care and Use Committee (IACUC) of the University of 
Utah Health Sciences Center. WT C57BL/6 mice between the ages of 7 and 8 days postnatal were 
anesthetized by rapid hypothermia on ice prior to rapid decapitation.  
The head was pinned to the sylgard plate and the skin and the connective tissues were 
removed. Using fine scissors, the skull was cut along the sutures to separate the interparietal 
region of the skull. This resulted in the exposure of superior colliculus, inferior colliculus and 
cerebellum. Ice-cold aCSF was applied to keep the tissue moist and cold. A one-sided razor blade 
was used to make a deep cut along the interface between the inferior colliculus and cerebellum, 
followed by removal of the cerebellum to isolate the brainstem. The brainstem and upper cervical 
spinal cord were isolated in ice-cold aCSF, bubbled with Carbogen. The brainstem was glued to a 
slant agar block using cyano acrylate with its rostral end up and its dorsal side attached to an agar 
block which was mounted and secured on a specimen tray. The agar block was cut at a slant 
forming a 110 degree angle between the agar block surface and the horizontal specimen tray (20 
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degree angle from vertical). The vibratome blade was set to a 20 degree angle below horizontal, 
which consequently sliced at a right angle to the surface of the agar block. Slicing at this angle 
enabled us to observe the projections from preBötC to the XII nucleus and from the XII nucleus 
to the rootlets.  
We sectioned the brainstem serially from a rostral to caudal direction. The first slice was 
cut at a thickness of 200 µm from the top (rostral end). From this point onwards, slices were 
made to observe facial nerves (first landmark). It varied with preparations, but usually a slice of 
400-500 µm from the top had to be removed to observe facial nerves. These facial nerves were 
observed over a thickness of 250-300 µm. Thus, a slice of 300 µm was made from the point of 
observing facial nerve. The next landmark was to observe the opening of ventricle at the 
brainstem-agar block interface. A slice of ~300-400 µm was cut to reveal the opening of the 
ventricle. From this point, slices of 200 µm were cut until the ventricle closed. The last three 
slices before the complete ventricle closure were taken and were called rostral, medial and caudal, 
respectively. To ensure that we were cutting at the level of the preBötC, we calculated the 
percentage of substance P (a marker for preBötC) responsive Class B cells within dissociated cell 
cultures obtained from each slice: as expected, the 200-µm-thick medial slice, on average, had the 
highest percentage of Substance P responsive cells (8.6%) compared to the rostral (7.3%) and 
caudal (4.1%) slices (n = 7 preparations). This suggested that the medial slice, on average, was 
near the center of the preBötC. In these slices, a faint hypoglossal nerve was observed and the 
nucleus ambiguus was sometimes observed in the rostral slice.  
The medial slice was placed in ice-cold HBSS, where the segments that contained the 
VRC and preBötC were microdissected and then transferred with a large-diameter fire-polished 
Pasteur pipette to a 15-mL conical tube. The total volume was adjusted to 900 µL with HBSS. 
Then 100 µL 2.5% (wt/vol) trypsin was added (for a working concentration of 0.25% (wt/vol) 
trypsin), and the tube was incubated at 37 °C in a water bath for 3-4 minutes. After incubation, 
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the intact tissue segments were washed three times with 4 mL MEM + supplements. Each wash 
was performed by adding 4 mL MEM + supplements, allowing microdissected segments to settle 
to the bottom of the tube, and removing as much medium as possible with a fire-polished Pasteur 
pipette while avoiding the accidental removal of any tissue. After the final wash, the tissue 
segments were resuspended in 1.5 mL MEM + supplements. The VRC suspension was triturated 
5–10 times (or until there was no resistance) through a series of fire-polished pipettes, where each 
successive pipette had a smaller tip diameter. The solution became cloudy as individual cells 
dissociated from the slice.  
The cell suspension was centrifuged at 50 × g for 10 minutes. After centrifugation of the 
cell suspension, the supernatant was removed by aspiration, leaving behind the volume of 
medium required to plate dissociated VRC neurons, typically into six wells (130 µL total). 
Neurons were resuspended in the remaining medium by gentle trituration with a 100 µL 
disposable plastic pipette tip. In several of the inner wells of a 24-well plate, 20 µL of the cell 
suspension was placed in the center of a 3 mm inner-diameter silicone ring, attached to the floor 
of each well, as described previously (Teichert et al., 2012b). The wells at the edge of the plate 
were half-filled with sterile water to humidify the culture. Each plate was then placed in the 37 °C 
incubator for 45–60 minutes to allow cells to settle and adhere. One mL MEM + supplements 
solution was added very gently at the edge of each well to avoid dislocating any loosely adherent 
cells within the silicone ring. The plates were placed in a 37 °C, 5% CO2 tissue culture incubator, 
and the cultures were used for imaging after 18–36 hours.  
Calcium imaging.  We have previously described the calcium-imaging methods in detail 
(Teichert et al., 2012a; Teichert et al., 2012b). Briefly, the cells were loaded with Fura-2-AM in 
their growth medium for 1 hour at 37 degrees C, followed by 30 minutes at room temperature, 
after which the medium containing Fura-2-AM was replaced with aCSF at room temperature for 
calcium imaging. Changes in cytoplasmic calcium concentration, [Ca2+]c, were monitored over 
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time by standard ratiometric calcium imaging methods, i.e. the ratio of fluorescence intensities at 
510 nm obtained from intermittent (typically once per two seconds) excitation by 340 nm and 380 
nm light (labeled as “340/380 nm” in Y-axis of calcium-imaging figures and described as 
“340/380 nm ratio” in the text). Upward or downward deflection of a calcium-imaging trace 
represents an increase or decrease in [Ca2+]c, respectively. In all figures, arrows indicate a 15-
second application of the specified compound or other perturbation. Horizontal bars indicate 
when other compounds were present in the bath solution. 
Statistical analysis.  The values shown under “Average response to 100 mM [K+]e ± 
S.D.” in Table 4.1 were calculated using all of the individual responses of Class A, B and C cells 
from 5 independent experimental trials, where “S.D.” is the standard deviation calculated from all 
of the individual responses. The quantification of the response shown in Table 4.1 is the 
magnitude change in the 340/380 nm ratio elicited by 100 mM [K+]e, as described above, and as 
depicted in the Y-axis of traces from Figure 4.1. Larger numbers indicate a greater response or 
greater relative change in [Ca2+]c elicited by 100 mM [K+]e. In the Results section, the p-value 
reported for the difference between Class A and B cells in the average response to 100 mM [K+]e 
was derived as follows: for each independent experimental trial (each trial included more than 
100 cells), a sample mean was calculated separately for Class A and B cells for the response to 
100 mM [K+]e. Then the sample means for Class A and B cells were compared from five 
independent experimental trials using Student’s t-test (two-tailed, paired samples). 
 
Results 
 Calcium imaging of dissociated VRC cell cultures.  We prepared cultures of dissociated 
VRC cells as described in Materials and Methods. Briefly, for each culture, we prepared a 
brainstem slice of ~200 microns thick, at the level of the preBötC, from a postnatal day 7-8 (P7-
8) mouse. We followed the same experimental approach and same protocols that we developed 
for producing rhythmically active slice preparations (Lieske et al., 2000; Pena et al., 2004; 
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Ramirez et al., 1996).  The region containing the preBötC and surrounding VRC was micro-
dissected from the slice, after which the cells were dissociated by enzymatic (trypsin) and 
mechanical methods. Cells were cultured overnight, prior to performing calcium-imaging 
experiments. 
 In Figure 4.2, we show images of dissociated VRC cell cultures of inadequate, optimal 
and excessive density. In our hands, the optimal plating density was ~800 cells/mm2 (not all cells 
survive). This plating density allowed us to perform calcium-imaging experiments in which we 
could simultaneously monitor the individual responses of more than 100 cells, while avoiding an 
excessive number of cells that overlapped or made contact with neighboring cells. This enabled 
us to confidently report the intrinsic responses of individual cells in this study. 
 Figure 4.2 also shows an example of a VRC cell culture that was used for a calcium-
imaging experiment. Panels D-G in Figure 4.2 are images of the same field of view. Panel D is 
bright field image. Panel E is a fluorescence image of the same cells loaded with Fura-2-AM dye 
(380 nm excitation and 510 nm emission). Panel F is a pseudo-colored ratiometric image of cells 
loaded with Fura-2-AM dye at rest. The ratio of fluorescence intensities at 510 nm emission, 
when excited alternately with 340 nm and 380 nm light, provides a relative measure of 
cytoplasmic calcium concentration, [Ca2+]c. Panel G is a ratiometric image, immediately after a 
stimulus to which a subset of the cells in the culture responded with an increase in [Ca2+]c. 
Pharmacological profiling of VRC cells.  Figure 4.1 exemplifies calcium-imaging traces 
from selected VRC cells in response to a set of receptor agonists and to depolarization by a high 
concentration (e.g., 100 mM) of extracellular potassium (high [K+]e). Abbreviations and 
concentrations are summarized in Table 4.2 for each of the pharmacological agents and other 
cellular perturbations used in this study. Three major classes of cells within these cultures could 
be differentiated by their distinct response properties.  
The first major cell class, “Class A,” was defined by responsiveness to high [K+]e and by 
the lack of responses to a panel of receptor agonists (Fig. 4.1A and Table 4.1). The second major 
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cell class, “Class B,” was defined by responsiveness to high [K+]e and one or more receptor 
agonists tested (Fig. 4.1B and Table 4.1). Notably, responsiveness to glutamate was excluded as a 
criterion for classifying cells, because approximately 80% of both Class A and B cells responded 
to glutamate (a receptor agonist for both metabotropic and ionotropic receptors). However, only 
Class B cells responded to the other receptor agonists (Table 4.1). In fact, the majority of Class B 
cells responded to each of the receptor agonists, with the exceptions of the neuropeptides, 
substance P and bradykinin, to which a minority of the Class B cells responded (Table 4.1).  
On average, Class A cells responded to depolarization by high [K+]e with large transient 
increases in [Ca2+]c (Fig. 4.1A and Table 4.1), indicating that they express high levels of voltage-
gated calcium channels, characteristic of neurons. On average, Class B cells responded less 
strongly to depolarization by high [K+]e than Class A cells (Fig. 4.1B and Table 4.1). This 
difference was statistically significant (p-value = 0.001, Student’s t-test). It is presently unclear 
whether Class B cells are neurons, glia or a mixed population of neurons and glia.  
Class B cells were subdivided into subclasses, based on the response profiles of 
individual cells, as shown in Table 4.3. The subclasses depicted in Table 4.3 represent 82% of the 
Class B cells. Other Class B subclasses each represented less than 1% of the Class B cells, and 
were not included in Table 4.3. Table 4.3 demonstrates that there are many variant forms of Class 
B cells, which presumably play different functional roles within this medullary region. 
The third major cell class, “Class C,” is comprised of putative nonneuronal cells (glial 
cells and potentially other nonneuronal cells) that did not respond to depolarization by high [K+]e 
(or responded very weakly, i.e., change in 340/380 nm ratio < 0.1) (Fig. 4.1C and Table 4.1), 
suggesting that they do not express voltage-gated calcium channels, or only express very low 
levels, unlike neurons. A small minority of Class C cells responded to each of the receptor 
agonists tested (Table 4.1). However, when we reduced the resting [K+]e from 3 mM to 0.2 mM, 
30% of the Class C cells responded with an increase in [Ca2+]c (Fig. 4.3). Such responses 
(putatively mediated by Kir4.1) have been shown to be specific to astrocytes in the VRC (Hartel 
	   64	  
et al., 2007; Hartel et al., 2009). This evidence supports the hypothesis that many Class C cells 
are glial (astrocytes and other glial cells). Furthermore, none of the Class A cells responded to 0.2 
mM [K+]e, which also supports the hypothesis that Class A cells are all neurons.  Six percent of 
the Class B cells responded to 0.2 mM [K+]e, which suggests that some of the Class B cells are 
astrocytes. 
Glutamate-receptor expression in VRC cell classes.  Cells were parsed into Classes A, B 
and C by the following criteria: cells were considered Class A if they only responded to high 
[K+]e and Class B if they responded to high [K+]e and either ACh (in the absence of PNU) or ATP 
(Fig. 4.4). Class C cells were determined by the same criterion as in Table 4.1 (change in 
340/380nm ratio < 0.1 in response to high [K+]e). On average, the Class A cells exhibited greater 
responses to high [K+]e than Class B cells, as expected, and as demonstrated in Figure 4.4C.  
Notably, the majority of Class A cells functionally express NMDA receptors and metabotropic 
glutamate receptors, with or without detectable expression of non-NMDA (AMPA or kainate) 
receptors (Fig. 4.44A & C). In contrast to Class A cells, the majority of Class B cells functionally 
express AMPA and/or kainite receptors, but not NMDA receptors (Fig. 4.4B & C).  Class C cells 
also did not express NMDA receptors (Fig. 4.4C). 
NMDA-receptor subtype expression in VRC cell classes.  Cells were divided into Classes 
A, B and C in a similar manner to the criteria used to define cell types for glutamate-receptor 
expression, with the exception of the use of the marker Substance P and the absence of the marker 
ATP.  Cells were considered Class A if they responded only to high [K+]e and Class B if they 
responded simultaneously to high [K+]e and either ACh or SP.  Cells were considered to be Class 
C by the same criterion as in Table 4.1 (change in 340/380nm ratio < 0.1 in response to high 
[K+]e). Following a protocol to identify cell classes, Mg2+ was removed from the bath solution, 
and cells were assayed for NMDA receptor expression. Similar to experiments assessing 
glutamate-receptor expression, the majority of Class A cells express NMDA receptors, whereas 
the majority of Class B and Class C cells do not (Fig. 4.5A and 4.5B; Table 4.4.). ConRl-B, a 
	   65	  
conopeptide that selectively blocks NMDA receptor subtypes containing the NR2B subunit, was 
administered following the first application of NMDA and D-serine, and block was measured 
during co-application with the second pulse of NMDA and D-serine (Fig. 4.5A and 4.5B).  
Notably, the majority (96%) of Class A cells were blocked by conRl-B, with an average block of 
68% (Figure 4.5A; Table 4.4).  In contrast, none of the Class B cells were blocked by conRl-B, 
indicating a relative lack of abundance of NR2B-containing NMDA receptor subtypes in this 
class (Fig. 4.5B; Table 4.4). Among cells in Class C, 50% were blocked by conRl-B, suggesting a 
mixture NMDA receptor subtypes are expressed in a small population (3%) of non-neuronal cells 
(Table 4.4).  NMDA-receptor mediated calcium signal in all cells that were either not blocked or 
partially blocked by conRl-B showed a complete inhibition by AP5, indicating the presence of 
non-NR2B NMDA receptor subtypes mediating calcium signal unblocked by conRl-B (Fig. 4.5A 
and 4.5B; Table 4.4). 
 
Discussion 
 Here, we show the characterization of VRC cell classes within the mouse brainstem at the 
level of the preBötC.  Three major cell classes, designated Class A, Class B, and Class C were 
identified.  It is notable that functional divergence within each cell class suggests that each of 
these major classes may be further subdivided into minor subclasses based on their 
responsiveness to the set of pharmacological tools used in this study.  With additional 
pharmacological markers, each subclass may ultimately be divided into specific cellular subtypes 
with distinct pharmacological roles.  A long-term goal of this work is to identify all of the cellular 
subtypes present in these cultures, to the point to where a physiological role for each cellular 
subtype may be inferred. 
On average, the Class A cells in this study responded strongly to a depolarizing stimulus.  
In addition, most Class A cells also responded to glutamate, but failed to respond to the other 
agonists tested (see Table 4.1).  Class B cells, in contrast, responded relatively weakly on average 
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to a depolarizing stimulus, with the majority of cells responding to an array of receptor agonists 
(Fig. 4.1 and Table 4.1).  Class C cells responded either very weakly or not at all to a depolarizing 
stimulus, suggesting that they potentially include glial cells or other nonneuronal cells (Fig 4.1 
and Table 4.1).  Approximately 30% of Class C cells responded to 0.2 mM [K+]e, a response 
suggesting that a proportion of Class C cells are astrocytes. 
Glutamate receptors were present in the majority of both Class A and Class B cells (Fig 
4.4).  Pharmacological dissection revealed that NMDA receptors are predominant in Class A 
cells, with concurrent expression of AMPA/Kainate receptors.  Among Class B cells, glutamate 
receptors largely belong to the AMPA/Kainate classes, with relatively little expression of NMDA 
receptors.  These data suggest a potential functional role for NMDA receptors among Class A 
cells.  It is notable that a large proportion (>50%) of Class A cells also tentatively express 
metabotropic glutamate receptors, as assessed by a glutamate-mediated calcium signal unaffected 
by CNQX (Figure 4.4).  Interestingly, both metabotropic glutamate receptors and NMDA 
receptors have been shown to contribute to inspiratory drive potentials in preBötC neurons, 
potentially through a common calcium-activated target (Pace et al., 2007).  Metabotropic 
glutamate receptors also have a modulatory role on NMDA receptor function in certain cell types 
(Conn and Pin, 1997).  Additional experiments using dissociated VRC cells can be used to reveal 
whether the functional relationships elucidated among NMDA receptors and metabotropic 
glutamate receptors correspond to particular cell types identified in this work. 
A distinction between NMDA receptor subtypes was also observed among the VRC cell 
classes.  Among Class A cells, NR2B subunit-containing NMDA receptors are the predominant 
subtype expressed (Table 4.4).  In contrast, among Class B cells, no NR2B subunit-containing 
NMDA receptor subtypes were detected (Fig. 4.5; Table 4.4).  Class B cells that respond to 
NMDA represent a relatively small proportion of the total population (approximately 2-5% in 
Class B; Fig. 4.4 and Table 4.4).  Nevertheless, this relatively small population of cells expressing 
non-NR2B-containing NMDA receptor subtypes may be functionally significant: VRC cells 
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responding to Substance P are hypothesized to be important for the generation of rhythmic 
breathing patterns (Palgiardini et al., 2005), and have been shown to co-express NMDA receptor 
protein in rats (Liu et al., 2001).  Thus, a distinct subtype of NMDA receptor may be present in 
cells that mediate vital respiratory function.  Through the use of additional subtype-selective 
NMDA receptor antagonists, future studies can begin to identify further NMDA receptor 
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Table 4.1. Summary of responses from the profiling experiments depicted in Figure 4.1. 
 
 















SP ACh ATP NE H B G 
Ventral Respiratory Column (P7-8 Mouse) 
Class A 0.8 ± 0.4 
Responsive to 
glutamate only & 
response to 100 mM 
[K+]e ≥ 0.1 
220 13% 0% 0% 0% 0% 0% 0% 78% 
Class B 0.3 ± 0.2 
Responsive to other 
receptor agonists & 
response to 100 mM 
[K+]e ≥ 0.1 
574 33% 8% 91% 68% 65% 74% 35% 76% 
Class C 0.0 ± 0.0 Response to 100 mM [K+]e < 0.1 
965 55% 1% 6% 8% 4% 5% 6% 6% 
 
The “Average response to 100 mM [K+]e ± S.D.” is a relative measure of the change in [Ca2+]c 
elicited by 100 mM [K+]e (i.e., change in 340/380 nm ratio shown in figures and described in 
Materials and methods). Larger numbers indicate a greater response or greater relative change in 
[Ca2+]c elicited by high [K+]e. The VRC data set was compiled from five independent 
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Table 4.2. Abbreviations of compounds cited in figures and tables. 
Abbreviation Compound Working Concentration 
ACh Acetylcholine 1 mM 
AP5 2-amino-5-phosphopentanoic acid 100 µM 
ATP Adenosine 5’ triphosphate 20 µM 
B Bradykinin 10 µM 
C Control  NA 
CNQX 6-cyano-7-nitroquinoxaline-2,3-
dione 
10 µM  
ConRl-B ConantokinRl-B 3.3 µM  
G Glutamate 300 µM 
H Histamine 50 µM 
K [K+]e 100 mM 







SP Substance-P 1 µM 
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Table 4.3. Subclasses of VRC Class B cells. 





- + + + + - + 128 22% 
- + + + + + + 84 15% 
- + - + + + + 33 6% 
- + - + + - + 30 5% 
- + + - + - + 30 5% 
- + + - - - + 22 4% 
- + - - - - + 21 4% 
+ + + + + - + 15 3% 
+ + + + + + + 13 2% 
- + - - + - + 12 2% 
- + + - - - - 12 2% 
- + - - + + + 10 2% 
- + + + + - - 10 2% 
- + + + - - + 10 2% 
- + + - + + + 9 2% 
- + + + + + - 8 1% 
- + - + + + - 8 1% 
- + + - + - - 7 1% 
 
Subclasses were sorted in order of observed frequency within Class B cells. These subclasses 
represent 82% of the Class B cells. Shading and “+” indicates responsiveness and “-” indicates 
lack of responsiveness to the respective compounds. This data set was compiled from five 
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Table 4.4. NR2B subunit-containing NMDA receptor expression among VRC cell classes 
Cell Class % Responsive 









Class A 79% 96% 68% (25%) 
Class B 5% 0% 0% (0%) 
Class C 3% 50% 33% (38%) 
 
Average block represents the percent inhibition of calcium signal amplitude.  Data set was 















































Figure 4.1. Example calcium-imaging traces from dissociated VRC cells in culture. Each trace is 
the response of a single cell to the experimental protocol depicted at the bottom of the figure. In 
each experimental trial, the individual responses of >100 cells were monitored simultaneously. 
The X-axis and experimental protocol at the bottom of the figure apply to all traces in the figure. 
The units of the X-axis are time in minutes.  The arrows identify time points when various types 
of stimuli were applied to the cells for 15 seconds. The abbreviations for these stimuli are defined 
in Table 4.2. “C” represents a control that is the replacement of bath solution (aCSF) with 
identical bath solution, which allowed us to exclude cells from further analysis that responded to 
the mere exchange of bath solution. The Y-axis for each trace is the ratio of fluorescence 
intensities obtained at 510 nm emission from the alternating excitation by 340 nm or 380 nm 
light.  It is a measure of relative changes in [Ca2+]c. The aforementioned facts also apply to 
Figures 4.3 – 4.5. These traces were obtained from an experimental protocol employing a set of 
receptor agonists and high [K+]e. (A) Example traces from Class A cells. Both cells responded 
strongly to depolarization by high [K+]e, but only one responded to glutamate with an increase in 
[Ca2+]c. (B) Example traces from Class B cells. Notably, these cells responded less strongly to 
high [K+]e, than Class A cells. They typically responded to several receptor agonists, as shown. 
(C) Example traces from Class C cells. These either did not respond to depolarization by high 






































Figure 4.2. Bright field images of dissociated VRC cells in culture. This shows cells of 
inadequate density (A), optimal density (B) and excessive density (C) for calcium-imaging 
experiments.  Cells were plated at the following densities for these images: (A) 400 cells/mm2, 
(B) 800 cells/mm2 and (C) 2000 cells/mm2. (D-G) Same field of view. (D) Bright field image of 
dissociated VRC cells. (E) Fluorescence image of the cells loaded with Fura-2-AM dye (380 nm 
excitation and 510 nm emission). (F) Pseudo-colored ratiometric image of cells at rest. The 
ratiometric image is a relative measure of [Ca2+]c, which is obtained from the ratio of 
fluorescence intensities obtained at 510 nm emission by alternately exciting by 340 nm and 380 
nm light. (G) Pseudo-colored ratiometric image of cells immediately following a stimulus, 
demonstrating that only a subset of the cells responded to the stimulus with an increase in [Ca2+]c 



















Figure 4.3. Example calcium-imaging traces demonstrating responses to 0.2 mM [K+]e in VRC 
Class C cells, and the lack of responses to 0.2 mM [K+]e in Class A and B cells. (A) Two 
examples are shown of Class A cells that did not respond to 0.2 mM [K+]e with an increase in 
[Ca2+]c. (B) Two examples are shown of Class B cells that did not respond to 0.2 mM [K+]e. (C) 
Two examples (top two traces) are shown of Class C cells that did not respond to 0.2 mM [K+]e 
with an increase in [Ca2+]c and three examples (bottom three traces) are shown of Class C cells 
that did respond to 0.2 mM [K+]e with an increase in [Ca2+]c.  
 


















Figure 4.4. Example calcium-imaging traces from experiments investigating glutamate receptors 
in VRC cells. The black horizontal bar indicates when 100 µM AP5 (NMDA receptor inhibitor) 
was present in the bath, which did not block the response to the second application of 300 µM 
glutamate. The open horizontal bar indicates when 10 µM CNQX (AMPA/kainite receptor 
inhibitor) was present in the bath. CNQX had differential effects on Class A and B cells. The grey 
horizontal bar (last bar to the right) indicates when the bath solution (aCSF) was changed to 
Mg2+-free aCSF, because Mg2+ blocks NMDA receptors (without a depolarizing stimulus; 
compare with NMDA/D-Ser application at minute 22). This demonstrated that Class A cells 
expressed NMDA receptors but Class B cells generally did not. (A) Example traces from Class A 
cells. (B) Example traces from Class B cells. (C) Compilation of data for Class A and B cells. 
This data set was compiled for 435 cells from 6 independent experimental trials, using cells 
















































Figure 4.5.  Example traces from calcium-imaging protocol investigating NMDA receptor 
subtype expression in VRC cells.  The light-grey horizontal bar indicates replacement of aCSF 
with Mg2+-free aCSF solution in the bath.  The open horizontal bar indicates when 3.3 µM conRl-
B (a NR2B-selective NMDA receptor inhibitor) was present in the bath.  The dark-grey 
horizontal bar indicates when 100 µM AP5 was present in the bath.  (A) Example traces from 
Class A cells.  The majority of Class A cells were either partially blocked (top) or completely 
blocked (bottom) by conRl-B.  (B) Example traces from Class B cells.  The majority of Class B 
cells did not respond to NMDA (bottom). Among Class B cells that responded to NMDA, none 
were blocked by conRl-B (top).   This data set was compiled for 575 cells from 5 independent 
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Summary 
In Chapters 2, 3, and 4, three different approaches were taken to further the development 
and applicability of utilizing conantokin peptides for the development of selective NMDA 
receptor antagonists.  In Chapter 2, a structure-activity relationship approach was used to identify 
sequence determinants of conantokin peptides that govern selectivity towards NR2D subunit-
containing NMDA receptor subtypes.  The work in Chapter 3 addresses a similar question by 
localizing regions on the NR2 subunits important for Conantokin-R and ConantokinRl-B 
discrimination between NR2D- and NR2B-containing NMDA receptor subtypes.  Lastly, the 
experiments in Chapter 4 address the applicability of utilizing highly selective conantokins to 
identify particular NR2 subunits expressed in particular cell types in a localized brain region. 
 
Significance of findings and perspectives for future research: Chapter 2 
Two key findings are reported in Chapter 2: the discovery and functional characterization 
of a conantokin that has a high potency on NR2D-containing NMDA receptor subtypes, and the 
identification of amino acid position 5 as a determinant for NR2D potency in the conantokins 
Con-R and Con-Br.  The combination of these two findings has had a significant impact on 
subsequent research.  Conus brettinghami, the species from which Con-Br was isolated, belongs 
to the Asprella clade of cone snails.  Molecular phylogeny, a research approach by which 
discovery of novel peptides (with desirable pharmacological properties) is guided by utilizing the 
phylogenetic relationship between species to search for homologous peptides in closely related 
species, has been successfully used to discover and characterize alpha-conotoxins of desired 
target specificity (Olivera, 2006).   Using this strategy, combined with sequence predictions 
guided our structure-activity relationship data, we identified, synthesized, and functionally 
characterized three conantokins from another species in the Asprella clade, Conus bocki, with 
novel pharmacologies: each of these three peptides had an unprecedented inhibitory preference 
(among conantokin peptides) for NR2D-containing NMDA receptor subtypes over those 
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containing other NR2 subunits (Platt et al., submitted).  These subsequent findings demonstrate 
the power of combining sequence prediction data with guided phylogenetic searches to identify 
novel pharmacological tools. 
 The finding that the amino acid at position 5 in Con-R and Con-Br is important for 
inhibition of NR2D subunit-containing NMDA receptor subtypes, is in addition, of significance 
in determining the basis for NR2 subunit selectivity in conantokin peptides.  In particular, the 
conclusions that can be drawn from this study are that sequence determinants can be used to 
predict selectivity towards the NR2D subunit.  Interestingly, prior studies have indicated that the 
amino acids at Positions 5 and 8 (and others) also govern selectivity among the NR2A and NR2B 
subunits in other conantokins (Klein et al., 2001; Sheng et al., 2007; Sheng et al., 2010).  Thus, 
certain common amino acid positions are potentially important for distinguishing among all of the 
NR2 subunits.  It is notable that not all conantokins appear to selectively inhibit NMDA receptor 
subtypes by a common set of sequence determinants.  For instance, structure activity studies of 
ConRl-B show no effect the substitution of the amino acid ad position 5 on subunit selectivity, 
and rather, amino acids at positions 8-10 including a lysine at position 8, appear to be important 
determinants (Gowd et al., 2012).  It is therefore possible that structural differences may 
contribute to conantokin selectivity in addition to sequence determinants.  A corollary of this 
hypothesis is that different sets of interactions at distinct amino acid positions could occur 
between different conantokins and the same NR2 subunit to govern selective inhibition.  A 
particular peptide “scaffold,” or milieu of amino acid sequences, may therefore be important for 
exhibiting selective preference over particular NR2 subunits.  Future studies to reveal the crystal 
structures of novel conantokin peptides, in their free form, as well as bound to NMDA receptors, 
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Significance of findings and perspectives for future research: Chapter 3 
The results of key significance in Chapter 3, are that Con-R and ConRl-B interact with 
both subdomains of the glutamate binding pocket (S1 and S2) to determine selectivity between 
the NR2B and NR2D subunits.  Moreover, specific NR2 subunit mutants were used to determine 
that Con-R and ConRl-B likely interact with similar regions of the subunits, but through a distinct 
set of amino acid residues.  These results can be interpreted in the context of the findings from 
Chapter 2 to provide insight into how conantokins and NR2 subunits are likely to interact to 
distinguish among the various NMDA receptor subtypes.  The conclusions in Chapter 2 and 
Gowd et al. (2012) suggest that, because the peptide determinants of selectivity on Con-R and 
ConRl-B occur at different positions, interactions governing selectivity on the NR2 subunits are 
predicted to occur through distinct sets of amino acids.  Consistent with this prediction, the 
double point mutant NR2D [D531Y; I534V] had an increase in effects on sensitivity to Con-R, 
but not ConRl-B (Chapter 3, Figs. 3.3 & 3.5).  It is also notable that these two peptides interacted 
similarly with NR2 subunit mutants that had larger regions of substitution than a few amino acids.  
These results indicate that the positioning for these two peptides within the glutamate-binding 
pocket (and likely other conantokins) are largely similar.  Future studies utilizing mutant cycle 
analysis can reveal precise points of interaction between Con-R, ConRl-B and the NR2B and 
NR2D subunits.  Such studies could examine, for instance, whether coupling occurs between the 
valine to tyrosine substitution at position 5 in Con-R and either of the amino substitutions D531Y 
or I34V in the NR2D subunit.  
Other studies have indicated that another conantokin, ConG, discriminates between the 
NR2A subunit and NR2B subunit through two amino acids in the S2 subdomain of the glutamate 
binding pocket (Sheng et al., 2009).  While this is not inconsistent with the findings reported in 
this dissertation, it is interesting to note that a single locus of interaction was identified for ConG 
on the NR2A and NR2B subunits, while multiple loci of interaction are suggested by results 
assessing the effects of Con-R and ConRl-B on NR2B and NR2D mutants.  One explanation of 
	   85	  
this is that the differences in the number of discriminatory sites may vary among conantokins for 
each NR2 subunit.  Thus, the NR2B and NR2D subunits may simply have more sites for 
conantokin discrimination than the NR2A and NR2B subunits.  One could easily test this 
hypothesis through the use of ConRl-B (which also discriminates between the NR2A and NR2B 
subunits) using a similar set of mutants, to determine whether the loci of discrimination overlap 
with ConG.  Additional work investigating the points of interaction for each conantokin-subunit 
combination could lead to predictions that could be utilized as rationale for the discovery and 
design of novel and highly selective conantokin peptides. 
 
Significance of findings and perspectives for future research: Chapter 4 
Three principal findings are described in Chapter 4: first, it was demonstrated that 
through Constellation Pharmacology, cells in the ventral respiratory column can be divided into 
three broad cell classes; second, it was demonstrated that differences in glutamate receptor types 
occur among the cell classes; and third, we show that selective conantokins can be used to 
identify differences in NMDA receptors subtypes among different cell types.  These are among 
the first experiments to identify NMDA receptor subtypes in particular cell types using 
conantokins.  The results show that Class A cells are largely NR2B-predominant, whereas Class 
B cells have a notable absence of NR2B-containing NMDA receptor subtypes.  Presumably, 
Class A cells and Class B cells have unique functional roles within the functional network of the 
preBötC.  Indeed, cells responding to Substance P (presumably a subpopulation of Class B cells 
identified in our assay), have been linked to critical functioning in the ventral respiratory column 
(Palgiardini et al., 2005).  Further experiments using conantokins with more broad 
pharmacologies such as Con-R (which targets both NR2A- and NR2B-subunit-containing NMDA 
receptor subtypes; see Chapter 2) can be used to dissect the NMDA receptor subtypes present in 
the Class B cell population.  
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These results are of further significance because application of NMDA receptor 
antagonists have been associated with certain types of network activity in the preBötC, such as 
enhancing fictive sighs and inhibiting normal breathing patterns, that are distinct from other 
glutamate receptors (Lieske and Ramirez, 2005). A greater understanding of how NMDA 
receptors function in different cell types could lead to insight into how these particular cells 
behave in functioning networks.  Through Constellation Pharmacology, we can begin to make 
predictions regarding which cell types may correspond to functioning cells within an intact brain 
region, and test these predictions through electrophysiological recordings.  Such an approach has 
been used to predict VRC cell types responding to Substance P that function in whole brain slices 
(Raghuraman et al., in preparation). In future studies, the development and use of selective 
conantokins in dissociated cell calcium-imaging assays, brain slice preparations, and whole 
animals, will hopefully reveal the functional roles of these NMDA receptor subtypes in the VRC 
and other brain regions. 
 
 Therapeutic applications of subtype selective conantokins 
 The conantokins discovered and characterized thus far have shown effectiveness in both 
clinical and preclinical trials for the treatment of various nervous system diseases.  ConG has 
reached phase I clinical trials for the treatment of epilepsy in humans (Bialer et al., 2002).  In 
addition, five conantokins have shown preclinical efficacy in animal models of pain, epilepsy, or 
neuroprotection following ischemia (Gowd et al., 2012; Jiminez et al., 2002; Malmberg et al., 
2003; Twede et al., 2009; White et al., 2000;; Williams et al., 2000).  Some small molecule 
compounds have been developed that preferentially target some NMDA receptor subtypes (such 
as NR2B) with a high degree of selectivity (Fischer et al., 1997); however, conantokins have the 
added advantage of lacking off-target activity on non-NMDA receptor targets (Gowd et al., 
2012).  Thus, conantokin peptides may prove highly useful in targeting NMDA receptor subtypes 
in whole animal systems with a great deal of specificity. 
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Notably, not all conantokins are equivalent in their efficacy or toxicity in preclinical 
models of disease (Twede et al., 2009).  For instance, ConG appears to exhibit less behavioral 
toxicity than ConT in models of pain, and certain ConG analogs appear to be more effective at 
inhibiting pain than their native peptide counterparts (Malmberg et al., 2003; Xiao et al., 2008). 
Interestingly, the conantokins that are most effective or exhibit the fewest side effects, are 
generally more selective for NR2B-containing NMDA receptor subtypes than their counterparts. 
Thus, high selectivity of conantokin peptides may correlate with improved efficacy and reduced 
toxicity in preclinical models of disease.  ConantokinRl-B shows an approximate 100-fold 
selectivity for NR2B-containing NMDA receptor subtypes over any other NMDA receptor 
subtype, and has demonstrated anticonvulsant activity in mice (Gowd et al., 2012), and is the 
most NR2B-selective conantokin identified to date. One hypothesis that merits further testing is 
that ConRl-B will exhibit greater efficacy and less toxicity than other conantokins when 
compared in other animal models of nervous system dysfunction.   
 The testing of highly selective conantokins in additional models of disease is also of 
potential therapeutic relevance. Recently, inhibition of NR2B and NR2D NMDA receptor 
subtypes was shown to alleviate A-Beta-induced inhibition of long-term potentiation in a rat 
model of Alzheimer’s disease (Zhang et al., 2013).  Selective conantokins that block NR2B- or 
NR2D- containing NMDA receptor subtypes could therefore be of potential use in treating early 
symptoms of Alzheimer’s disease.  NR2B-selective conantokins have further potential use in a 
number of disorders leading to cell death.  ConG was found to promote cell survival in 
hippocampal neurons, whereas a less NR2B- selective conantokin (ConT) was found to be less 
effective (Balsara et al., 2012).  This effect has been attributed to the preferential inhibition of cell 
death extrasynaptic NMDA receptor-mediated pathways associated with NR2B subtypes (Balsara 
et al., 2012).  NR2D-containing NMDA receptors may also be associated with cell death, as 
proteins that negatively regulate the function of the NR2D subunit are thought to promote cell 
survival by the inhibition of this NMDA receptor subtype (Bai et al., 2013).   NR2D is expressed 
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at the highest levels in midbrain structures in the central nervous system (Laurie et al., 1997).  
The development of NR2D-selective conantokins is therefore of potential benefit in devising 
effective strategies for promoting cell survival in disorders that affect this region of the brain, 
such as dopaminergic loss in substantia nigra cells in Parkinson’s disease. 
 It should be noted that potential therapeutic applications for selective conantokin peptides 
need to ideally be considered on a disease-specific basis.  One potential caveat of studies of 
NMDA receptor subunit expression in normal mammalian systems, is that there may not be a 
complete correspondence with the subtype expression in pathogenic animals.  For instance, 
certain models of epilepsy show a differences in expression of NR2A, but not NR2B subtypes 
(Gibbs et al., 2011; Zhu et al., 2004).  Contrastingly, some models of neuropathic pain show an 
increase in NR2B expression (Wilson et al., 2005).  This underscores the need to develop a 
toolkit of highly selective conantokins for many NMDA receptor subtypes, which can then be 
evaluated for further therapeutic merit in the context of specific nervous system pathologies.  
Thus far, conantokins have been discovered that target NR2B-containing NMDA receptor 
subtypes while simultaneously targeting various other NR2 subunit combinations.  The discovery 
of NR2D-preferring conantokins, and the findings described in this dissertation point towards the 
potential for developing highly selective conantokins for each particular NMDA receptor subtype.  
The continued development of these novel compounds may lead to a pharmacological toolkit that 
can be used to target an array of nervous system disorders. 
 
Scientific contributions of this work 
The experiments in this dissertation essentially tackle two broad questions.  First, how do 
we go about developing highly subtype-selective NMDA receptor antagonists from a particular 
class of conopeptides?  Second, can a highly selective conantokin peptide be used to identify 
NMDA receptor subtypes in the nervous system?  Through structure-function studies and 
structure-activity relationship studies, this work has provided insights that have already been used 
	   89	  
to predict conantokin peptide sequences with novel inhibitory activities.  Hopefully, this work 
will provide additional information that may be used to achieve this objective.  By testing 
selective conantokin peptides in dissociated cell calcium imaging assays, we have begun to 
identify particular NMDA receptor subtypes in particular brain regions and cell types.  It is hoped 
that the continued development of selective conantokins will reveal further distinctions among 
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